| Literature
>>> |
| NBIA Disorders Association
Medical Literature |
| This
list has been compiled from several different sources for easy reference
on articles concerning NBIA disorders including PKAN, INAD, atypical NAD,
Idiopathaic NBIA, Neuroferritinopathy and Aceruloplasminemia, or
other topics relevant to understanding these disorders. They are listed in
chronological order, most recent first. If you wish copies of any
articles, most can be found at university medical libraries where you
live, or you may be able to order them online. |
|
Please Note: If you are looking for articles written before 1985, try a Pub Med Query at http://www.ncbi.nlm.nih.gov This is also a good site to go to for any additional information or queries for journal articles on other related topics. |
|
HUNTINGTON'S DISEASE PHENOCOPIES ARE CLINICALLY AND GENETICALLY HETEROGENEOUS. Wild EJ,et.al. Mov Disord. (Jan 7, 2008). [Epub ahead of print] EXPRESSION OF A MUTANT FORM OF THE FERRITIN LIGHT CHAIN GENE INDUCES NEURODEGENERATION AND IRON OVERLOAD IN TRANSGENIC MICE. Vidal R, et.al. Journal of Neuroscience. (Jan 2, 2008; 28(1)). Pp. 60-7. MICROGLIA AND ASTROGLIA PREVENT OXIDATIVE STRESS-INDUCED NEURONAL CELL DEATH: IMPLICATIONS FOR ACERULOPLASMINEMIA. Oshiro S, et.al. Biochim Biophys Acta. (Dec 15, 2007. [Epub ahead of print]. PREVENTION AND RESTORATION OF LACTACYSTIN-INDUCED NIGROSTRIATAL DOPAMINE NEURON DEGENERATION BY NOVEL BRAIN-PERMEABLE IRON CHELATORS. Zhu W, et.al. FASEB J. (Dec 2007; 21(14)). Pp.3835-44. Epub 2007 Aug 9. PALLIDAL STIMULATION FOR DYSTONIA IN PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Shields DC, et.al. Pediatric Neurology. (Dec 2007; 37(6)). Pp. 442-5. CYS-881 IS ESSENTIAL FOR THE TRAFFICKING AND SECRETION OF TRUNCATED MUTANT CERULOPLASMIN IN ACERULOPLASMINEMIA. Kono S, et.al. J Hepatol. (Dec 2007; 47(6)). Pp. 844-50. Epub (Jun 18, 2007). ANTICHOLINERGIC-RESPONSIVE GAIT FREEZING IN A PATIENT WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Lyoo CH, et.al. Movement Disorders. (Nov 12, 2007; [Epub ahead of print]). A NOVEL PANK2 GENE MUTATION: CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS SHORT COMMUNICATION. Kazek B, et.al Journal of Childhood Neurology. (Nov 2007; 22(11)). Pp.1256-9. IRON HOMEOSTASIS AND TOXICITY IN RETINAL DEGENERATION. He X, et.al. Prog Retin Eye Res. (Nov 2007; 26(6)). Pp. 649-73. Epub (Aug 11, 2007). ACERULOPLASMINEMIA WITH PROGRESSIVE ATROPHY WITHOUT BRAIN IRON OVERLOAD: TREATMENT WITH ORAL CHELATION. Skidmore FM, et.al. Journal of Neurological Neurosurgy Psychiatry. (Oct 2, 2007); [Epub ahead of print] IRON TOXICITY AS A POTENTIAL FACTOR IN AMD. Wong RW, et.al. Retina. (Oct 2007; 27(8)). Pp. 997-1003. NEUROPATHOLOGY, BIOCHEMISTRY, AND BIOPHYSICS OF ALPHA-SYNUCLEIN AGGREGATION. Uversky VN. Journal of Neurochemistry. (Oct 2007; 103(1)). Pp. 17-37. Epub (Jul 10, 2007). NOVEL MUTATION IN THE PANK2 GENE LEADS TO PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION IN A PAKISTANI FAMILY. Saleheen D, et.al. Pediatric Neurology. (Oct 2007; 37(4)). Pp. 296-8. PATHOLOGY OF HEPATIC IRON OVERLOAD. Deugnier Y, Turlin B. World J Gastroenterol. (Sep 21, 2007; 13(35)). Pp. 4755-60. NEURORESCUE ACTIVITY, APP REGULATION AND AMYLOID-BETA PEPTIDE REDUCTION BY NOVEL MULTI-FUNCTIONAL BRAIN PERMEABLE IRON- CHELATING- ANTIOXIDANTS, M-30 AND GREEN TEA POLYPHENOL, EGCG.Avramovich-Tirosh Y, et.al. Current Alzheimer Res. (Sep 2007; 4(4)). Pp. 403-11. THE HUNTINGTON'S DISEASE-LIKE SYNDROMES: WHAT TO CONSIDER IN PATIENTS WITH A NEGATIVE HUNTINGTON'S DISEASE GENE TEST. Schneider SA, et.al. National Clinical Practice in Neurology. (Sep 2007; 3(9)). Pp. 517-25. IDENTIFICATION AND IN SILICO CHARACTERIZATION OF A NOVEL COMPOUND HETEROZYGOSITY ASSOCIATED WITH HEREDITARY ACERULOPLASMINEMIA. Hofmann WP, et.al. Scand J Gastroenterology. (Sep 2007;42(9)). Pp. 1088-94. HOMEOSTATIC MECHANISMS FOR IRON STORAGE REVEALED BY GENETIC MANIPULATIONS AND LIVE IMAGING OF DROSOPHILA FERRITIN. Missirlis F, et.al. Genetics. (Sep 2007; 177(1)). Pp. 89-100. Epub (Jul 1, 2007). ESTABLISHING A BASELINE PHASE BEHAVIOR IN MAGNETIC RESONANCE IMAGING TO DETERMINE NORMAL VS. ABNORMAL IRON CONTENT IN THE BRAIN. Haacke EM, et.al. Journal of Magnetic Resonate Imaging. (Aug 26, 2007 (2)). Pp. 256-64. SURGERY FOR OTHER MOVEMENT DISORDERS: DYSTONIA, TICS. Curr Opin Neurol. Hamani C & Moro E. (Aug 2007; 20(4)). Pp. 470-6. THE REDOX CHEMISTRY OF THE ALZHEIMER'S DISEASE AMYLOID BETA PEPTIDE. Smith DG, et.al. Biochim Biophys Acta. (Aug 2007; 1768(8)). Pp. 1976-90. Epub (Feb 9, 2007). FERRITIN IN AUTOIMMUNE DISEASES. AUTOIMMUN REV. Zandman-Goddard G, Shoenfeld Y. (Aug 2007; 6(7)). Pp. 457-63. Epub (Feb 16, 2007). TREATMENT OF SYMPTOMATIC HETEROZYGOUS ACERULOPLASMINEMIA WITH ORAL ZINC SULPHATE. Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Brain Dev. (Aug 2007; 29(7)). Pp.450-3. Epub (Feb 20, 2007). FERROXIDASE ACTIVITY IS REQUIRED FOR THE STABILITY OF CELL SURFACE FERROPORTIN IN CELLS EXPRESSING GPI-CERULOPLASMIN. De Domenico I, et.al. EMBO J. (Jun 20, 2007; 26(12)). Pp. 2823-31. Epub (May 31, 2007). DEPRIVATION OF PANTOTHENIC ACID ELICITS A MOVEMENT DISORDER AND AZOOSPERMIA IN A MOUSE MODEL OF PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Kuo YM, et.al. Journal of Inherit Metabolism Discovery. (Jun 2007; (30)(3)). Pp. 310-7. Epub (Apr 12, 2007). INTELLECTUAL AND ADAPTIVE BEHAVIOUR FUNCTIONING IN PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Freeman K, et.al. Journal of Intellectual Disability Research. (Jun 2007; 51(Pt. 6)). Pp. 417-26. MANAGEMENT OF STATUS DYSTONICUS: OUR EXPERIENCE AND REVIEW OF THE LITERATURE. Mariotti P, et.al. Movement Disorders. (May 15, 2007; 22(7)). Pp. 963-8. FERROPORTIN1 AND HEPHAESTIN ARE INVOLVED IN THE NIGRAL IRON ACCUMULATION OF 6-OHDA-LESIONED RATS. Wang J, et.al. European Journal of Neuroscience. (May 2007; 25(9)). Pp. 2766-72. CEREBELLAR ATROPHY WITHOUT CEREBELLAR CORTEX HYPERINTENSITY IN INFANTILE NEUROAXONAL DYSTROPHY (INAD) DUE TO PLA2G6 MUTATION. Biancheri R, et.al. Eur J Paediatr Neurol. (May 2007; 11(3)). Pp. 175-7. Epub (Jan 24, 2007). DIFFERENTIAL CEREBRAL CORTEX TRANSCRIPTOMES OF BABOON NEONATES CONSUMING MODERATE AND HIGH DOCOSAHEXAENOIC ACID FORMULAS. Kothapalli KS, et.al. PLoS ONE. (Apr 11, 2007; 2(4)). Pp. e370. RELAXATION AND SUSCEPTIBILITY MRI CHARACTERISTICS IN HALLERVORDEN-SPATZ SYNDROME. Vinod Desai S, et.al. Journal of Magnetic Resonate Imaging. (Apr 2007; 25(4)). Pp.715-20. BRAIN FERRITIN IRON MAY INFLUENCE AGE- AND GENDER-RELATED RISKS OF NEURODEGENERATION. Bartzokis G, et.al. Neurobiological Aging. (Mar 2007; 28(3)). Pp. 414-23. Epub (Mar 24, 2006). NEURODEGENERATION WITH BRAIN IRON ACCUMULATION: CLINICAL, RADIOGRAPHIC AND GENETIC HETEROGENEITY AND CORRESPONDING THERAPEUTIC OPTIONS. Clement F, et.al. Acta Neurol Belg. (Mar 2007;107(1)). Pp. 26-31. ADULT-ONSET NEURODEGENERATION WITH BRAIN IRON ACCUMULATION AND CORTICALALPHA-SYNUCLEIN AND TAU PATHOLOGY: A DISTINCT CLINICOPATHOLOGICAL ENTITY. Tofaris Gk, et.al. Arch Neurology. (Feb 2007 (2)). Pp. 280-2. NEUROLOGIC PHENOTYPES ASSOCIATED WITH ACANTHOCYTOSIS. Walker RH, et.al. Neurology. (Jan 9, 2007; 68(2)). Pp.92-8. PANTOTHENATE-KINASE ASSOCIATED NEURODEGENERATION (PKAN) "EYE OF THE TIGER" SIGN. Renaud DL & Kotagal S. Pediatric Neurology. (Jan 2007; 36(1)). Pp.70-1. PRELIMINARY OBSERVATION OF ELEVATED LEVELS OF NANOCRYSTALLINE IRON OXIDE IN THE BASAL GANGLIA OF NEUROFERRITINOPATHY PATIENTS. Hautot D, et.al. Biochim Biophys Acta. (Jan 2007; 1772(1)). Pp. 21-5. Epub (Oct 6, 2006). CLINICAL FEATURES AND NATURAL HISTORY OF NEUROFERRITINOPATHY CAUSED BY THE FTL1 460INSA MUTATION. Chinnery PF, et.al. Brain. (Jan 2007; 130(Pt 1)). Pp. 110-9. Epub 2 (Dec 2006). MOVEMENT DISORDER DUE TO ACERULOPLASMINEMIA AND INCORRECT DIAGNOSIS OF HEREDITARY HEMOCHROMATOSIS. Fasano A, et.al. J Neurol. (Jan 2007; 254(1)).Pp.113-4. Epub (Feb 14, 2007). CLINICAL SIGNIFICANCE OF THE LABORATORY DETERMINATION OF LOW SERUM COPPER IN ADULTS. Kumar N, et.al. Clin Chem Lab Med. (2007; 45(10)). Pp.1402-0. ANALYSIS OF FERRITIN GENES IN PARKINSON DISEASE. Foglieni B, et.al. Clin Chem Lab Med. (2007;45(11)). Pp. 1450-6. LONG-TERM BENEFIT TO PALLIDAL DEEP BRAIN STIMULATION IN A CASE OF DYSTONIA SECONDARY TO PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Krause M, et.al. Movement Disorders. (Dec 2006; 21(12)). Pp. 2255-7. NOVEL MUTATION IN THE CERULOPLASMIN GENE CAUSING A COGNITIVE AND MOVEMENT DISORDER WITH DIABETES MELLITUS. Shang HF, et.al. Movement Disorders. (Dec 2006; 21(12)). Pp. 2217-20 IRON INDUCED OXIDATIVE DAMAGE AS A POTENTIAL FACTOR IN AGE-RELATED MACULAR DEGENERATION: THE COGAN LECTURE. Dunaief JL. Invest Ophthalmol Vis Sci. (Nov 2006; 47(11)). Pp 4660-4. PLA2G6 MUTATION UNDERLIES INFANTILE NEUROAXONAL DYSTROPHY. Khateeb S, et.al. American Journal of Human Genetics. (Nov 2006; 79(5)). Pp. 942-8. Epub (Sep 19, 2006). [GENETIC IRON OVERLOAD DISEASES: A DEEPLY CHANGING WORLD]. Brissot P, et.al. Nephrol Ther. (Nov 2006; 2 Suppl 5). Pp. S298-303. Review. French. PANK2 GENE ANALYSIS CONFIRMS GENETIC HETEROGENEITY IN NEURODEGENERATION WITH BRAIN IRON ACCUMULATION (NBIA) BUT MUTATIONS ARE RARE IN OTHER TYPES OF ADULT NEURODEGENERATIVE DISEASE. Matarin MM, et.al. Neuroscience Letters. (Oct 23, 2006; 407(2)). Pp. 162-5. Epub (Sep 2006 7.) NEUROSURGICAL TREATMENT IN CHILDHOOD DYSTONIAS AND DYSKINESIAS. Gil-Robles S, et.al. Rev Neurology. (Oct 10, 2006; 43 Suppl 1). Pp. S169-72. Spanish. DEPOSITION OF IRON AND BETA-AMYLOID PLAQUES IS ASSOCIATED WITH CORTICAL CELLULAR DAMAGE IN RABBITS FED WITH LONG-TERM CHOLESTEROL-ENRICHED DIETS. Ghribi O, et.al. Journal of Neurochemistry. (Oct 2006; 99(2)). Pp. 438-49. ACERULOPLASMINEMIA (HEREDITARY CERULOPLASMIN DEFICIENCY) AND DIABETES MELLITUS. Momoki T, Terauchi Y. Nippon Rinsho. (Sep 28, 2006; Suppl 3. P100-4.) Review. Japanese. SEVERE TONGUE PROTRUSION DYSTONIA: CLINICAL SYNDROMES AND POSSIBLE TREATMENT. Schneider SA, et.al. Neurology. (Sep 26, 2006; 67(6)). Pp. 940-3. AGE-RELATED CHANGES IN IRON HOMEOSTASIS AND CELL DEATH IN THE CEREBELLUM OF CERULOPLASMIN-DEFICIENT MICE. Jeong SY & David S. Journal of Neuroscience. (Sep 20, 2006; 26(38)) Pp. 9810-9. IRON METABOLISM IN PARKINSONIAN SYNDROMES. Berg D & Hochstrasser H. Movement Disorders. (Sep 2006; 21(9)). Pp. 1299-310. NEURODEGENERATION WITH BRAIN IRON ACCUMULATION: FROM GENES TO PATHOGENESIS. Hayflick SJ. Seminar Pediatric Neurology. (Sep, 2006; 13(3)). Pp. 182-5. Review. NEUROFERRITINOPATHY. Burn J, & Chinnery PF. Seminar Pediatric Neurology. (Sep, 2006; 13(3)). Pp. 176-81. BRAIN IRON METABOLISM. Rouault TA & Cooperman S. Seminar Pediatric Neurology. (Sep, 2006; 13(3)) Pp. 142-8. Review. DELAYED CHANGES IN T1-WEIGHTED SIGNAL INTENSITY IN A RAT MODEL OF 15-MINUTE TRANSIENT FOCAL ISCHEMIA STUDIED BY MAGNETIC RESONANCE IMAGING/SPECTROSCOPY AND SYNCHROTRON RADIATION X-RAY FLUORESCENCE. Wang X, et.al. Magnetic Resonate Medicine. (Sep 2006; 56(3)). Pp.474-80. NEUROFERRITINOPATHY. Burn J, Chinnery PF. Semin Pediatr Neurol. (Sep 2006; 13(3)). Pp. 176-81. CERULOPLASMIN IS A NO OXIDASE AND NITRITE SYNTHASE THAT DETERMINES ENDOCRINE NO HOMEOSTASIS. Shiva S, et.al. Nat Chem Biol. (Sep 2006; 2(9)). Pp. 486-93. Epub (Aug 13, 2006). HALLERVORDEN SPATZ DISEASE. Sabat SB & Deshmukh MP. J Assoc Physicians India. (Aug 2006; 54:629). HALLERVOREDN-SPATZ DISEASE. Asad Maqbool Ahmad, et.al. J Coll Physicians Surg Pak. (Aug 2006; 16(8)). Pp. 545-7. PANTOTHENATE KINASE 2 MUTATION WITH CLASSIC PANTOTHENATE-KINASE-ASSOCIATED NEURODEGENERATION WITHOUT 'EYE-OF-THE-TIGER' SIGN ON MRI IN A PAIR OF SIBLINGS. Zolkipli Z, et.al. Pediatric Radiology. (Aug 2006; 36(8)). Pp.884-6. Epub 2006 Jun 7. INCREASED UPTAKE OF DIVALENT METALS LEAD AND CADMIUM INTO THE BRAIN AFTER KAINITE-INDUCED NEURONAL INJURY. Ong WY, et.al. Exp Brain Res. (Aug 2006; 173(3)). Pp. 468-74. Epub (Mar 22, 2006). A 70-YEAR-OLD MAN WITH EXTRAPYRAMIDAL SYMPTOMS, DEMENTIA AND HEMOSIDEROSIS. Chrétien F, et.al. Brain Pathol. (Jul 2006; 16(3)). Pp. 235-6. NEURODEGENERATION WITH FEATURES OF NIFID AND ALS--EXTENDED CLINICAL AND NEUROPATHOLOGICAL SPECTRUM. Roeber S, et.al. Brain Pathology. (Jul 2006; 16(3)). Pp. 228-34. PLA2G6 ENCODING A PHOSPHOLIPASE A2, IS MUTATED IN NEURODEGENERATIVE DISORDERS WITH HIGH BRAIN IRON. Morgan NV, et.al. National Genetics. (Jul 2006; 38(7)). Pp. 752-4. (Aug 2006; 38(8)). Pp. 957. GENE SYMBOL: PANK2. DISEASE: PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (PKAN). Westaway SK, et.al. Human Genetics. (Jul 2006; 119(6)). Pp. 671-679. HEPATIC IRON OVERLOAD ASSOCIATED WITH A DECREASED SERUM CERULOPLASMIN LEVEL IN A NOVEL CLINICAL TYPE OF ACERULOPLASMINEMIA. Kono S, et.al Gastroenterology. (July 2006; 131(1)). Pp. 240-5. CLINICAL HETEROGENEITY IN HALLERVORDEN-SPATZ SYNDROME: A CLINICORADIOLOGICAL STUDY IN 13 PATIENTS FROM SOUTH INDIA. Bindu PS, et.al. Brain Dev. (Jul 2006; 28(6)). Pp.343-7. Epub (Feb 28, 2006). QUIESCENCE INDUCED BY IRON CHALLENGE PROTECTS NEUROBLASTOMA CELLS FROM OXIDATIVE STRESS. Mura CV, et.al. Journal of Neurochemistry. (Jul 2006; 98(1)). Pp. 11-9. BRAIN MRI IN NEURODEGENERATION WITH BRAIN IRON ACCUMULATION WITH AND WITHOUT PANK2 MUTATIONS. Hayflick SJ, et.al. (AJNR) American Journal of Neuroradiology. (Jun-Jul 2006; 27(6)). Pp.1230-3. PANK2 MUTATION SCREENING RECOMMENDED TO CONFIRM DIAGNOSIS OF PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Gregory A & Hayflick SJ. AJNR Am J Neuroradiol. (May 2006; 27(5)). Pp. 951. PARTIAL DEFICIT OF PANTOTHENATE KINASE 2 CATALYTIC ACTIVITY IN A CASE OF TREMOR-PREDOMINANT NEURODEGENERATION WITH BRAIN IRON ACCUMULATION. Liang TW, et.al. Movement Disorders. (May 2006; 21(5)). Pp.718-22. THE IRON CARRIER TRANSFERRIN IS UPREGULATED IN RETINAS FROM PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. Chowers I, et.al. Invest Ophthalmol Vis Sci. (May 2006; 47(5)). Pp.2135-40. HALLERBORDEN SPATZ DISEASE. Raji V, et.al. Journal of Association of Physicians of India. (Apr 2006; 54) Pp.320-2. IDENTIFICATION OF AXONAL INVOLVEMENT IN HALLERVORDEN-SPATZ DISEASE WITH MAGNETIC RESONANCE SPECTROSCOPY. Kitis O, et.al. J Neuroradiol. (Apr 2006; 33(2)). Pp.129-32. DEFENDING EPONYMS. Fox RJ. Arch Neurol. (Apr 2006; 63(4)). Pp. 628 IRON OVERLOAD AND ANTIOXIDATIVE ROLE OF PERIVASCULAR ASTROCYTES IN ACERULOPLASMINEMIA. Oide T, et.al. Neuropathol Appl Neurobiol. (Apr 2006; 32(2)). Pp.170-6. GENETIC, CLINICAL, AND IMAGING CHARACTERIZATION OF ONE PATIENT WITH LATE-ONSET, SLOWLY PROGRESSIVE, PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Antonini A, et.al. Move Disorders. (Mar 2006; 21(3)). Pp. 417-8. PARKINSON-PLUS-SYNDROMES. Nacimiento W. bFortschr Neurol Psychiatr. (Mar . 2006; 74(3). Pp.165-78; quiz 179-80. German. SPONTANEOUS MURINE NEUROAXONAL DYSTROPHY: A MODEL OF INFANTILE NEUROAXONAL DYSTROPHY. Bouley DM, et.al. Journal of Comp Pathology. (Feb-Apr 2006; ROLE OF IRON IN NEURODEGENERATIVE DISORDERS. Berg D, Youdim MB. Top Magnet Resonate Imaging. (Feb 17, 2006 (1)). Pp 5-17. GENOTYPIC AND PHENOTYPIC SPECTRUM OF PANK2 MUTATIONS IN PATIENTS WITH NEURODEGENERATION WITH BRAIN IRON ACCUMULATION. Hartig MB, et.al. Annals of Neurology. (Feb 2006; 59(2)). Pp. 248-56. GREEN TEA CATECHINS AS BRAIN-PERMEABLE, NATURAL IRON CHELATORS-ANTIOXIDANTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS. Mandel S, et.al. Molecular Nutrition Food Res. (Feb 2006; 50(2)). Pp. 229-34. ROLE OF IRON IN NEURODEGENERATIVE DISORDERS. Berg D & Youdim MB. Top Magnetic Resonate Imaging. (Feb 2006; 17(1)). Pp.5-17. GENETIC HETEROGENEITY IN PATIENTS WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION AND CLASSIC MAGNETIC RESONANCE IMAGING EYE-OF-THE-TIGER PATTERN. Valentino P, et.al. Movement Disorders. Feb 2006; 21(2)). Pp.252-4. EFFECT OF NEONATAL BODY TEMPERATURE ON POSTANOXIC, POTENTIALLY NEUROTOXIC IRON ACCUMULATION IN THE RAT BRAIN. Rogalska J, et.al. Neuroscientific Letters. (Jan 30, 2006; 393(2-3)). Pp. 249-54. Epub (Nov 10, 2005). BIOCHEMICAL PROPERTIES OF HUMAN PANTOTHENATE KINASE 2 ISOFORMS AND MUTATIONS LINKED TO PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Zhang YM, et.al. J Biol Chem. (Jan 6, 2006; 281(1)). Pp. 107-14. Epub (Nov 3, 2005). TAU-PREDOMINANT-ASSOCIATED PATHOLOGY IN A SPORADIC LATE-ONSET HALLERVORDEN-SPATZ SYNDROME. Zarranz JJ, et.al. Mov Disord. (Jan 2006; 21(1)). Pp. 107-11. STAGED BILATERAL STEREOTACTIC PALLIDOTHALAMOTOMY FOR LIFE-THREATENING DYSTONIA IN A CHILD WITH HALLERVORDEN-SPATZ DISEASE. Balas I,et. al. Movement Disorders. (Jan 2006; 21(1)). Pp. 82-5. PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION WITH INCREASED LENTIFORM NUCLEI CEREBRAL BLOOD FLOW. Koyama M, Yagishita A. AJNR Am J Neuroradiol. (Jan 2006; 27(1)). Pp. 212-3. BIOCHEMICAL FEATURES OF CERULOPLASMIN GENE MUTATIONS LINKED TO ACERULOPLASMINEMIA. Kono S, et.al. Neuromolecular Medicine. (2006); 8(3)). Pp. 361-74. NEURODEGENERATION WITH BRAIN IRON ACCUMULATION: A CAUTIONARY TALE. Pearce JM. European Journal of Neurology. (2006; 56(1)). Pp. 66-8. Review. IRON AND GLUTATHIONE AT THE CROSSROAD OF REDOX METABOLISM IN NEURONS. Aracena P, et.al. Biol Res. (2006; 39(1)). Pp.157-65. MOLECULAR AND PATHOLOGICAL BASIS OF ACERULOPLASMINEMIA. Kono S, Miyajima H. Biol Res. (2006; 39(1)). Pp.15-23. EXCLUSION OF MUTATIONS IN THE PRNP, JPH3, TBP, ATN1, CREBBP, POU3F2 AND FTL GENES AS A CAUSE OF DISEASE IN PORTUGUESE PATIENTS WITH A HUNTINGTON-LIKE PHENOTYPE. Costa Mdo C, et.al. J Hum Genet. (2006; 51(8)). Pp. 645-51. Epub (Jul 21, 2006). A NOVEL 3-BP DELETION IN THE PANK2 GENE OF DUTCH PATIENTS WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION: EVIDENCE FOR A FOUNDER EFFECT. Rump P, et.al. Neurogenetics. (Dec 2005; 6(4)). Pp. 201-7. Epub (Oct 21, 2005). CERULOPLASMIN IN NEURODEGENERATIVE DISEASES. Vassiliev V, Harris ZL, Zatta P. Brain Res Brain Res Rev. (Nov 2005; 49(3)). Pp. 633-40. A NOVEL MUTATION IN A PATIENT WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Saleheen D, et.al. CMAJ. (Sep 13, 2005; 173(6)). Pp. 578-9. DISTINCT ROLES OF OXIDATIVE STRESS AND ANTIOXIDANTS IN THE NUCLEUS DORSALIS AND RED NUCLEUS FOLLOWING SPINAL CORD HEMISECTION. Xu M, et.al. Brain Res. (Sep 7, 2005; 1055(1-2)). Pp. 137-42. NEUROFERRITINOPATHY: MISSENSE MUTATION IN FTL CAUSING EARLY-ONSET BILATERAL PALLIDAL INVOLVEMENT. Maciel P, et.al. Neurology. (Aug 23, 2005; 65(4)). Pp.603-5. NEURO-OPHTHALMOLOGIC AND ELECTRORETINOGRAPHIC FINDINGS IN PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (FORMERLY HALLERVORDEN-SPATZ SYNDROME). Egan RA, et.al. Am J Ophthalmol. (Aug 2005; 140(2)). Pp. 267-74. NEUROACANTHOCYTOSIS. Danek A, Walker RH. Curr Opin Neurol. (Aug 2005; 18(4)). Pp. 386-92. FRONTAL LOBE DYSFUNCTION ASSOCIATED WITH GLUCOSE HYPOMETABOLISM IN ACERULOPLASMINEMIA. Miyajima H, et.al. J Neurol. (Aug 2005; 252(8)). Pp. 996-7. Epub (Mar 16, 2005). EFFECTS OF DEVELOPMENT AND IRON STATUS ON CERULOPLASMIN EXPRESSION IN RAT BRAIN. Chang YZ, et.al. J Cell Physiol. (Aug 2005; 204(2)). Pp. 623-31. PROGRESSIVE DEGENERATION OF HUMAN MESENCEPHALIC NEURON-DERIVED CELLS TRIGGERED B DOPAMINE-DEPENDENT OXIDATIVE STRESS IS DEPENDENT ON THE MIXED-LINEAGE KINASE PATHWAY. Lotharius J, et.al. Journalof Neuroscience. (Jul 6, 2005; 25(27)). Pp.6329-42. ATYPICAL HALLERVORDEN-SPATZ DISEASE WITH PRESERVED COGNITION AND OBTRUSIVE OBSESSIONS AND COMPULSIONS. Nicholas AP, et.al. Movement Disorders. (Jul 2005; 20(7)). Pp. 880-6. NOVEL COMPOUND HETEROZYGOUS MUTATIONS IN THE PANK2 GENE IN A CHINESE PATIENT WITH ATYPICAL PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Zhang YH, et.al. Movement Disorders. (Jul 2005; 20(7)). Pp. 819-21. ACERULOPLASMINEMIA IN AN ASYMPTOMATIC PATIENT WITH A NEW MUTATION. DIAGNOSIS AND FAMILY GENETIC ANALYSIS. Pérez-Aguilar F, Burguera JA, Benlloch S, Berenguer M, Rayón JM. J Hepatol. (June 2005; 42(6)). Pp. 947-9. Epub (Apr 7, 2005). THE NEUROTRANSMITTER NORADRENALINE RESCUES SEPTAL CHOLINERGIC NEURONS IN CULTURE FROM DEGENERATION CAUSED BY LOW-LEVEL OXIDATIVE STRESS. Traver S, et.al. Molecular Pharmacology. (Jun 2005; 67(6)). Pp.1882-91. Epub (Mar 22, 2005). FIRST CASES IN THE CZECH REPUBLIC OF THE HALLERVORDEN-SPATZ DISEASE RESULTING FROM MUTATION IN THE PANTOTHENATE KINASE 2 GENE. Zumrová A, et.al. Neuro Endocrinol Lett. (Jun 2005; 26(3)). Pp. 213-8. THE EYE-OF-THE-TIGER SIGN IS NOT A RELIABLE DISEASE MARKER FOR HALLERVORDEN-SPATZ SYNDROME. Baumeister FA, et.al. Neuropediatrics. (Jun 2005; 36(3)). Pp. 221-2. RECALLING PLAIN BEAUTIES. Degnan M. Nursing. (June 2005; 35(6)). Pp. b52. NEUROFERRITINOPATHY: A NEURODEGENERATIVE DISORDER ASSOCIATED WITH L-FERRITIN MUTATION. Levi S, Cozzi A, Arosio P. Best Pract Res Clin Haematol. (June 2005; 18(2)). Pp.265-76 MACULAR DEGENERATION IN A PATIENT WITH ACERULOPLASMINEMIA, A DISEASE ASSOCIATED WITH RETINAL IRON OVERLOAD. Dunaief JL, et.al. Ophthalmology. (June 2005; 112(6). Pp. 1062-5. THE DIVERSE PHENOTYPE AND GENOTYPE OF PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Pellecchia MT, et.al. Neurology. (May 24, 2005; 64(10)). Pp.1810-2. MUTATIONS IN THE PANTOTHENATE KINASE GENE PANK2 ARE NOT ASSOCIATED WITH PARKINSON DISEASE. Klopstock T, et.al. Neurosci Lett. (May 13, 2005; 379(3)). Pp.195-8. PALLIDAL STIMULATION IMPROVES PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Castelnau P, et.al. Ann Neurol. (May 2005; 57(5)). Pp. 738-41. MR RELAXOMETRY AND 1H MR SPECTROSCOPY FOR THE DETERMINATION OF IRON AND METABOLITE CONCENTRATIONS IN PKAN PATIENTS. Hájek M, et.al. Eur Radiol. (May 2005; 15(5)). Pp1060-8. Epub (Nov 24, 2004). GENE SYMBOL: PANK2. DISEASE: PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN). Wieczorek S, Epplen JT. Human Genetics. (May 2005; 116(6)). Pp. 535, 545. RECOGNITION MEMORY IMPAIRMENT AND BRAIN OXIDATIVE STRESS INDUCED BY POSTNATAL IRON ADMINISTRATION. de Lima MN, et.al. European Journal of Neuroscience. (May 2005; 21(9)). Pp. 2521-8. ELECTRON TOMOGRAPHY OF DEGENERATING NEURONS IN MICE WITH ABNORMAL REGULATION OF IRON METABOLISM. Zhang P, et.al. Journal of Structual Biology. (May 2005; 150(2)). Pp.144-53. HEREDITARY FERRITINOPATHY: A NOVEL MUTATION, ITS CELLULAR PATHOLOGY, AND PATHOGENETIC INSIGHTS. Mancuso M, et.al. J Neuropathol Exp Neurol. (Apr 2005; 64(4)). Pp. 280-94. NEUROACANTHOCYTOSIS: NEW DEVELOPMENTS IN A NEGLECTED GROUP OF DEMENTING DISORDERS. Danek A, et.al. J Neurol Sci. (Mar 15, 2005; 229-230). Pp. 171-86. Epub (Jan 7, 2005). PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (HALLERVORDEN-SPATZ SYNDROME). Kapoor S, et.al. Indian J Pediatr. (Mar 2005; 72(3)). Pp. 261-3. HALLERVORDEN SPATZ DISEASE: MR AND PATHOLOGICAL FINDINGS OF A RARE CASE. Sharma MC, et.al. Neurol India. (Mar 2005; 53(1)). Pp. 102-4. MR IMAGING OF CEREBRAL CORTICAL INVOLVEMENT IN ACERULOPLASMINEMIA. Grisoli M, et.al. (AJNR) American Journal of Neuroradiology. (Mar 2005; 26(3)). Pp. 657-61. A NEW MOUSE MODEL FOR INFANTILE NEUROAXONAL DYSTROPHY, INAD MOUSE, MAPS TO MOUSE CHROMOSOME 1. Matsushima Y, et.al. Mamm Genome. (Feb 2005; 16(2)). Pp. 73-8. CLINICAL AND NEUROPSYCHOLOGICAL CORRELATES IN TWO BROTHERS WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Marelli C, et.al. Movement Disorders. (Feb 2005; 20(2)). Pp. 208-12. CEREBELLAR HYPOPERFUSION IN INFANTILE NEUROAXONAL DYSTROPHY. Kóbor J, et.al. Pediatric Neurology. (Feb 2005; 32(2)). Pp.137-9. ADULT-ONSET GENERALIZED DYSTONIA DUE TO A MUTATION IN THE NEUROFERRITINOPATHY GENE. Mir P, Edwards MJ, Curtis AR, Bhatia KP, Quinn NP. Movememnt Disorders. (Feb 2005; 20(2)). Pp. 243-5. ALTERED NEURONAL MITOCHONDRIAL COENZYME A SYNTHESIS IN NEURODEGENERATION WITH BRAIN IRON ACCUMULATION CAUSED BY ABNORMAL PROCESSING, STABILITY, AND CATALYTIC ACTIVITY OF MUTANT PANTOTHENATE KINASE 2. Kotzbauer PT, et.al. Journal of Neuroscience. (Jan 19, 2005; 25(3)). Pp. 689-98. [123I]FP-CIT SPECT FINDINGS IN TWO PATIENTS WITH HALLERVORDEN-SPATZ DISEASE WITH HOMOZYGOUS MUTATION IN PANK2 GENE. Cossu G, et.al. Neurology. (Jan 11, 2005; 64(1)). Pp.167-8. THE "EYE OF THE TIGER" SIGN. Saleheen D, Frossard P, Ozair MZ, Kazmi MA, Khalid H, Khealani B. CMAJ. (Jan 4, 2005;172(1)). Pp. 38. DEFICIENCY OF PANTOTHENATE KINASE 2 (PANK2) IN MICE LEADS TO RETINAL DEGENERATION AND AZOOSPERMIA. Kuo YM, et.al. Hum Mol Genet. (Jan 1, 2005; 14(1)). Pp.49-57. Epub (Nov 3). SPECTRUM OF MOVEMENT DISORDERS IN NEUROFERRITINOPATHY. Crompton DE, Chinnery PF, Bates D, Walls TJ, Jackson MJ, Curtis AJ, Burn J. Mov Disord. (Jan 2005; 20(1)). Pp. 95-9. FERRITINOPATHY: DIAGNOSIS BY MUSCLE OR NERVE BIOPSY, WITH A NOTE ON OTHER NUCLEAR INCLUSION BODY DISEASES. Schröder JM. Acta Neuropathol. (Jan 2005; 109(1)). Pp. 109-14. Epub (Jan 11, 2005). NEURODEGENERATION WITH BRAIN IRON ACCUMULATION. Folia Neuropathology. Gregory A, et.al. (2005; 43(4)). Pp. 286-96. MULTIFUNCTIONAL ACTIVITIES OF GREEN TEA CATECHINS IN NEUROPROTECTION. MODULATION OF CELL SURVIVAL GENES, IRON-DEPENDENT OXIDATIVE STRESS AND PKC SIGNALING PATHWAY. Mandel SA, et.al. Neurosignals (2005; 14(1-2)). Pp. 46-60. THE CHOICE OF ANESTHESIA IN HALLERVORDEN-SPATZ DISEASE. Bujok G, Misiołek H. Wiad Lek. (2005; 58(11-12)). Pp, 682-4. Polish. DIETARY RESCUE OF FUMBLE--A DROSOPHILA MODEL FOR PANTOTHENATE-KINASE-ASSOCIATED NEURODEGENERATION. Yang Y, Wu Z, Kuo YM, Zhou B. Journal of Inherit Metab Dis. (2005; 28(6)). Pp.1055-64. RE: STATUS DYSTONICUS AND HALLERVORDEN-SPATZ DISEASE. Flett PJ. J Paediatr Child Health. (Dec 2004; 40(12)). Pp. 721. IRON, BRAIN AGEING AND NEURODEGENERATIVE DISORDERS. Zecca L, et.al. Nat Rev Neurosci. (Nov 2004; 5(11)). Pp. 863-73. [AUTOSOMAL DOMINANT SPINOCEREBELLAR DEGENERATION--NEW FORMS AND PATHOMECHANISMS]. Mizusawa H. Rinsho Shinkeigaku. (Nov 2004; 44(11)). Pp.782-4 PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION INITIALLY PRESENTING AS POSTURAL TREMOR ALONE IN A JAPANESE FAMILY WITH HOMOZYGOUS N245S SUBSTITUTIONS IN THE PANTOTHENATE KINASE GENE. Yamashita S, et.al. J Neurol Sci. (Oct 15, 2004;225(1-2)). Pp.129-33. [A CASE OF INFANTILE NEUROAXONAL DYSTROPHY]. Wu Y, et.al. Zhonghua Er Ke Za Zhi. (Oct 2004; 42(10)). Pp.796. Chinese. [A CASE OF ACERULOPLASMINEMIA PRESENTING AS CEREBELLAR ATAXIA WITH HOMOZYGOUS MUTATION NT2602 DELG]. Nagata M, et.al. No To Shinkei. (Oct 2004; 56(10)). Pp.885-9. Japanese. DISRUPTION OF CERULOPLASMIN AND HEPHAESTIN IN MICE CAUSES RETINAL IRON OVERLOAD AND RETINAL DEGENERATION WITH FEATURES OF AGE-RELATED MACULAR DEGENERATION. Hahn P, et.al. Proc Natl Acad Sci U S A. (Sep 21, 2004;101(38)). Pp. 13850-5. Epub (Sep 13, 2004). INFANTILE NEUROAXONAL DYSTROPHY AND PANTOTHENATE-KINASE-ASSOCIATED NEURODEGENERATION: LOCUS HETEROGENEITY. Hörtnagel K, et.al. Neurology. (Sep 14, 2004; 63(5)). Pp. 922-4. [HALLERVORDEN SPATZ SYNDROME: MAGNETIC RESONANCE FINDINGS. CASE REPORT]. Farage L, Castro MA, Macedo TA, Assis MC, Souza LP, Freitas LO. Arq Neuropsiquiatr. (Sep 2004; 62(3A)). Pp. 730-2. Epub (Aug 24, 2004). Portuguese. [NERVOUS SYSTEM MANIFESTATION IN ACERULOPLASMINEMIA]. Miyajima H. Nippon Naika Gakkai Zasshi. (Aug 10, 2004; 93(8)). Pnp.1579-84. Review. Japanese. DIFFUSION MAGNETIC RESONANCE IMAGING PATTERNS IN METABOLIC AND TOXIC BRAIN DISORDERS. Sener RN. Acta Radiol. (Aug 2004; 45(5)). Pp.561-70. IRON AND BRAIN DISORDERS. Sadrzadeh SM & Saffari Y. American Journal of Clinical Pathology. (Jun 2004;121). Suppl Pp.S64-70. A FUNGAL MULTICOPPER OXIDASE RESTORES IRON HOMEOSTASIS IN ACERULOPLASMINEMIA. Harris ZL, Davis-Kaplan SR, Gitlin JD, Kaplan J. Blood. (Jun 15, 2004; 103(12)). Pp. 4672-3. Epub (Jan 22, 2004). STATUS DYSTONICUS AND HALLERVORDEN-SPATZ DISEASE: TREATMENT WITH INTRATHECAL BACLOFEN AND PALLIDOTOMY. Kyriagis M, Grattan-Smith P, Scheinberg A, Teo C, Nakaji N, Waugh M. J Paediatr Child Health. (May-Jun 2004; 40(5-6)). Pp. 322-5. PALLIDAL DEEP BRAIN STIMULATION FOR LONGSTANDING SEVERE GENERALIZED DYSTONIA IN HALLERVORDEN-SPATZ SYNDROME. CASE REPORT. Umemura A, et.al. J Neurosurg. (Apr 2004; 100(4)). Pp. 706-9. ELECTROPHYSIOLOGICAL ASSESSMENT OF THE EFFECT OF INTRATHECAL BACLOFEN IN DYSTONIC CHILDREN. Dachy B & Dan B. Clin Neurophysiol. (Apr 2004; 115(4)). Pp. 774-8. INTRACELLULAR FERRITIN ACCUMULATION IN NEURAL AND EXTRANEURAL TISSUE CHARACTERIZES A NEURODEGENERATIVE DISEASE ASSOCIATED WITH A MUTATION IN THE FERRITIN LIGHT POLYPEPTIDE GENE. Vidal R, et.al. Journal of Neuropathology Exp Neurol. (Apr 2004; 63(4)). Pp. 363-80. MITOCHONDRIAL LOCALIZATION OF HUMAN PANK2 AND HYPOTHESES OF SECONDARY IRON ACCUMULATION IN PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Johnson MA, et.al. Annals of New York Academy of Science. (Mar 2004; 1012). Pp. 282-98. IRONING IRON OUT IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES WITH IRON CHELATORS: A LESSON FROM 6-HYDROXYDOPAMINE AND IRON CHELATORS, DESFERAL AND VK-28. Youdim MB, et.al. Annals of New York Academy of Sciences. (Mar 2004; 1012). Pp. 306-25. ACERULOPLASMINEMIA: AN INHERITED NEURODEGENERATIVE DISEASE WITH IMPAIRMENT OF IRON HOMEOSTASIS. Xu X, et.al. Annuals of New York Academy of Sciences. (Mar 2004; 1012). Pp. 299-305. HEREDITARY CAUSES OF DISTURBED IRON HOMEOSTASIS IN THE CENTRAL NERVOUS SYSTEM. Ponka P. Annuals of New York Academy of Sciences. (Mar 2004;1012). Pp. 267-81. [TOURETTISM, HEMIBALLISM AND JUVENILE PARKINSONISM: EXPANDING THE CLINICAL SPECTRUM OF THE NEURODEGENERATION ASSOCIATED TO PANTOTHENATE KINASE DEFICIENCY (HALLERVORDEN SPATZ SYNDROME)]. Carod-Artal FJ, et.al. Rev Neurol. (Feb 16-29, 2004; 38(4)). Pp. 327-31. Spanish. NEUROPROTECTION BY A NOVEL BRAIN PERMEABLE IRON CHELATOR, VK-28, AGAINST 6-HYDROXYDOPAMINE LESSION IN RATS. Shachar DB, et.al. Neuropharmacology. (Feb 2004; 46(2)). Pp. 254-63. CLINICAL HETEROGENEITY OF NEURODEGENERATION WITH BRAIN IRON ACCUMULATION (HALLERVORDEN-SPATZ SYNDROME) AND PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Thomas M, et.al. Movement Disorders. (Jan 2004; 19(1)). Pp. 36-42. A FUNGAL MULTICOPPER OXIDASE RESTORES IRON HOMEOSTASIS IN ACERULOPLASMINEMIA. Harris ZL, et.al. Blood. (Jun 15 2004; 103(12)). Pp. 4672-3. Epub (Jan 22, 2004). ALPHA-SYNUCLEIN: NORMAL FUNCTION AND ROLE IN NEURODEGENERATIVE DISEASES. Norris EH, et. al. Current Top Development Biology. (2004; 60). Pp.17-54. IRON AND ALPHA-SYNUCLEIN IN THE SUBSTANTIA NIGRA OF MPTP-TREATED MICE: EFFECT OF NEUROPROTECTIVE DRUGS R-APOMORPHINE AND GREEN TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE. Mandel S, et.al. Journal of Molecular Neuroscience. (2004; 24(3)). Pp. 401-16. ELEVATED LEVELS OF FERRIMAGNETIC METALS IN FOODCHAINS SUPPORTING THE GUAM CLUSTER OF NEURODEGENERATION: DO METAL NUCLEATED CRYSTAL CONTAMINANTS [CORRECTED] EVOKE MAGNETIC FIELDS THAT INITIATE THE PROGRESSIVE PATHOGENESIS OF NEURODEGENERATION? Purdey M. Medical Hypotheses. (2004; 63(5)) Pp.793-809. Erratum in: Med Hypotheses (2005; 65(6)). Pp. 1207. CLINICAL HETEROGENEITY OF NEURODEGENERATION WITH BRAIN IRON ACCUMULATION (HALLERVORDEN-SPATZ SYNDROME) AND PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION. Thomas M, et.al. Movement Disorders. (Jan 2004; 19(1)). Pp. 36-42. OFF-PERIOD DYSTONIA IN PARKINSON'S DISEASE BUT NOT GENERALIZED DYSTONIA IS IMPROVED BY HIGH-FREQUENCY STIMULATION OF THE SUBTHALAMIC NUCLEUS. Detante O, et.al. Adv Neurol. (2004; 94). Pp. 309-14. [GENETICS OF HEREDITARY IRON OVERLOAD]. Le Gall JY, et.al. Bull Acad Natl Med. (2004: 188(2)). Pp. 247-62; discussion 262-3. Review. French UNRAVELING THE HALLERVORDEN-SPATZ SYNDROME: PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION IS THE NAME. Hayflick SJ. Current Opinions in Pediatrics. (Dec 2003; 15(6)). Pp. 572-7. ACERULOPLASMINEMIA, AN IRON METABOLIC DISORDER. Miyajima H. Neuropathology. (Dec 2003; 23(4)). Pp. 345-50. COMPOUND HETEROZYGOUS PANK2 MUTATIONS CONFIRM HARP AND HALLERVORDEN-SPATZ SYNDROMES ARE ALLELIC. Houlden H, et.al. Neurology. (Nov 25, 2003; 61(10)). Pp. 1423-6. PSYCHOTIC DISORDER IN A CASE WITH HALLERVORDEN-SPATZ DISEASE. Oner O, et.al. Acta Psychiatr Scand. (Nov 2003; 108(5)). Pp. 394-7; discussion 397-8. PURE AKINESIA: AN UNUSUAL PHENOTYPE OF HALLERVORDEN-SPATZ SYNDROME. Molinuevo JL, et.al. Movement Disorders. (Nov 2003; 18(11)). Pp. 1351-3. CERVICAL MYELOPATHY IN AN ADOLESCENT WITH HALLERVORDEN-SPATZ DISEASE. Fung GP & Chan KY. Pediatr Neurol. (Oct 2003; 29(4)). Pp. 337-40. DOPAMINERGIC CELL DEATH PRECEDES IRON ELEVATION IN MPTP-INJECTED MONKEYS. He Y, Thong PS, et. al. Free Radical Biological Medicine. (Sep 1, 2003;35(5)). Pp. 540-7. NEUROPATHOLOGICAL SPECTRUM OF SYNUCLEINOPATHIES. Jellinger KA. Movement Disorders. (Sep 2003). Pp.18; Suppl 6 Pp. S2-12. PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION: MR IMAGING, PROTON MR SPECTROSCOPY, AND DIFFUSION MR IMAGING FINDINGS. Sener RN. AJNR Am J Neuroradiol. (Sep 2003; 24(8)). Pp. 1690-3. FAMILIAL PEDIATRIC RAPIDLY PROGRESSIVE EXTRAPYRAMIDAL SYNDROME: IS IT HALLERVORDEN-SPATZ DISEASE? Chakravarty A, et.al. Pediatr Neurol. (Aug 2003; 29(2)). Pp. 170-2. ELEMENT OF CAUTION: A CASE OF REVERSIBLE CYTOPENIAS ASSOCIATED WITH EXCESSIVE ZINC SUPPLEMENTATION. Irving JA, et.al. CMAJ. (Jul 22, 2003; 169(2)). Pp.129-31. GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED CERULOPLASMIN IS REQUIRED FOR IRON EFFLUX FROM CELLS IN THE CENTRAL NERVOUS SYSTEM. Jeong SY & David S. Journal of Biological Chemistry. (Jul18, 2003; 278(29)). Pp.27144-8. Epub (May 12, 2003). [MIXED HYPOTONIA, NEUROLOGICAL REGRESSION AND ATROPHY OF THE CEREBELLUM: MANIFESTATIONS THAT SUGGEST INFANTILE NEUROAXONAL DYSTROPHY]. Blanco-Barca MO, et. al. Rev Neurology. (Jul 1-15, 2003; 37(1)) Pp. 25-8. PART II: ALPHA-SYNUCLEIN AND ITS MOLECULAR PATHOPHYSIOLOGICAL ROLE IN NEURODEGENERATIVE DISEASE. Dev KK, et.al. Neuropharmacology. (Jul 2003;45(1)). Pp.14-44. ADULT HALLERVORDEN-SPATZ SYNDROME SIMULATING AMYOTROPHIC LATERAL SCLEROSIS. Vasconcelos OM, et.al. Muscle Nerve. (Jul 2003; 28(1)). Pp. 118-22. ACERULOPLASMINEMIA WITH JUVENILE-ONSET DIABETES MELLITUS CAUSED BY EXON SKIPPING IN THE CERULOPLASMIN GENE. Hatanaka Y, et.al. Intern Med. (Jul 2003;42(7)). Pp. 599-604. [ABOUT PANTOTHENATE KINASE DEFICIENCY-ASSOCIATED NEURODEGENERATION OR PKAN. Gilgenkrantz S. Med Sci (Paris). (Jun-Jul 2003; 19(6-7)). Pp. 668-70. French. HALLERVORDEN SPATZ DISEASE. Rao C, Murthy V, Hegde R, Asha, Vishwanath. Indian J Pediatr. (Jun 2003; 70(6)). Pp. 513-4. MAGNETIC RESONANCE IMAGING AND HALLERVORDEN-SPATZ SYNDROME. Trimble M. CNS Spectr. (Jun 2003; 8(6)). Pp. 420. TRANSGENIC MODELS OF ALPHA-SYNUCLEIN PATHOLOGY: PAST, PRESENT, AND FUTURE. Hashimoto M, et.al. Annuals of New York Academy of Science. (Jun 2003; 991). Pp. 171-88. METALLOTHIONEIN ATTENUATES 3-MORPHOLINOSYDNONIMINE (SIN-1)-INDUCED OXIDATIVE STRESS IN DOPAMINERGIC NEURONS. Sharma SK & Ebadi M. Antioxident Redox Signal. (Jun 2003; 5(3)). Pp. 251-64. HEME AND IRON METABOLISM: ROLE IN CEREBRAL HEMORRHAGE. Wagner KR, et.al. Journal of Cerebral Blood Flow Metabolism. (Jun 2003; 23(6)). Pp. 629-52. ASSOCIATION OF HFE MUTATIONS WITH NEURODEGENERATION AND OXIDATIVE STRESS IN ALZHEIMER'S DISEASE AND CORRELATION WITH APOE. Pulliam JF, et.al. American Journal of Medical Genetic B Neuropsychiatry Genetics. (May 15, 2003; 119(1)). Pp. 48-53. MRI DETECTION OF FERRITIN IRON OVERLOAD AND ASSOCIATED NEURONAL PATHOLOGY IN IRON REGULATORY PROTEIN-2 KNOCKOUT MICE. Grabill C, et.al. Brain Res. (May 2, 2003; 971(1)). Pp. 95-106. EYE-OF-THE-TIGER SIGN. Sethi NK & Sethi PK. J Assoc Physicians India. (May 2003; 51). Pp. 486. NEUROFERRITINOPATHY IN A FRENCH FAMILY WITH LATE ONSET DOMINANT DYSTONIA. Chinnery PF, et.al. J Med Genet. (May 2003; 40(5)). Pp. e69. HALLERVORDEN AND HISTORY. Leach JP. N Engl J Med. (Apr 24 2003; 348(17)). Pp. 1725-6; author reply 1725-6. HALLERVORDEN AND HISTORY. Geiderman JM. N Engl J Med. (Apr 24, 2003; 348(17)). Pp. 1725-6; author reply 1725-6. NEUROLOGICAL ASPECTS OF OSTEOPETROSIS. Steward CG. Neuropathology of Applied Neurobiology.(Apr 2003; 29(2)). Pp. 87-97. PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (FORMERLY HALLERVORDEN-SPATZ SYNDROME). Hayflick SJ. J Neurol Sci. (Mar 15, 2003; 207(1-2)). Pp. 106-7. CHILDHOOD DYSTONIA. Uc EY & Rodnitzky RL. Seminar Pediatric Neurology. (Mar 2003; 10(1)). Pp. 52-61. ACERULOPLASMINEMIA, AN INHERITED DISORDER OF IRON METABOLISM. Miyajima H, Takahashi Y, Kono S. Biometals. (Mar; 16(1)). Pp. 205-13. ACERULOPLASMINEMIA. Harris ZL. J Neurol Sci. (Mar 15, 2003; 207(1-2)). Pp.108-9. AN ISOFORM OF HPANK2, DEFICIENT IN PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION, LOCALIZES TO MITOCHONDRIA. Hörtnagel K, Prokisch H, Meitinger T. Hum Mol Genet. (Feb 1, 2003; 12(3)). Pp. 321-7. DIFFUSION MAGNETIC RESONANCE IMAGING IN INFANTILE NEUROAXONAL DYSTROPHY. Sener RN. J Comput Assist Tomogr. (Jan-Feb 2003; 27(1)). Pp.34-7. GENETIC, CLINICAL, AND RADIOGRAPHIC DELINEATION OF HALLERVORDEN-SPATZ SYNDROME. Hayflick SJ, et.al. New England Journal of Medicine. (Jan 2, 2003; 348(1)). Pp. 33-40. HALLERVORDEN AND HISTORY. Shevell M. The New England Journal of Medicine (Jan 2003; 348(1)). Pp. 3-4. WHAT HAVE WE LEARNT FROM CDNA MICROARRAY GENE EXPRESSION STUDIES ABOUT THE ROLE OF IRON IN MPTP INDUCED NEURODEGENERATION AND PARKINSON'S DISEASE? Youdim MB. Journal of Neural Transmission Suppl. (2003; (65)). Pp. 73-88. Review. PROGRESSIVE DYSTONIA IN A 12-YEAR-OLD BOY. Klepper J, Schaper J, Raca G, Coryell J, Das S, Hayflick SJ, Voit T. Eur J Paediatr Neurol. (2003; 7(2)). Pp. 85-8. A FAMILIAL CASE OF HALLERVORDEN-SPATZ DISEASE. Iudina GK, Sholomov II. Zh Nevrol Psikhiatr Im S S Korsakova. (2003; 103(1)). Pp. 49-50. Russian. QUANTITATIVE EVALUATION OF EXPRESSION OF IRON-METABOLISM GENES IN CERULOPLASMIN-DEFICIENT MICE. Yamamoto K, et.al. Biochim Biophys Acta. (Dec 12, 2002; 1588(3)). Pp. 195-202. INFANTILE NEUROAXONAL DYSTROPHY (SEITELBERGER'S DISEASE). Gordon N. Developmental Medicine in Child Neurology. (Dec 2002; 44(12)). Pp. 849-51. PHOSPHORYLATED ALPHA-SYNUCLEIN IS UBIQUITINATED IN ALPHA-SYNUCLEINOPATHY LESIONS. Hasegawa M, et al. J Biol Chem (Dec 2002; 277(50)). Pp. 49071-6. CERULOPLASMINE AND IRON METABOLISM: THEIR IMPLICATIONS IN HEMOCHROMATOSIS, WILSON'S DISEASE AND ACERULOPLASMINEMIA. Pérez-Aguilar F. Rev Clin Esp. (Dec 2002; 202(12)). Pp. 649-51. Spanish. ASTROCYTIC DEFORMITY AND GLOBULAR STRUCTURES ARE CHARACTERISTIC OF THE BRAINS OF PATIENTS WITH ACERULOPLASMINEMIA. Kaneko K, et.al. Jour of Neuropathol Exp Neurol. (Dec 2002; 61(12)). Pp.1069-77. TYPE I NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, (NBIA-I, FORMERLYHALLERVORDEN-SPATZ DISEASE). PART II NEUROPATHOLOGIC MANIFESTATION, NOVEL GENETIC ASPECTS AND PATHOGENESIS. Bertrand E. Neurol Neurochir of Poland. (Nov-Dec 2002; 36(6)). Pp. 1163-71. Polish. INCREASED LIPID PEROXIDATION AND MITOCHONDRIAL DYSFUNCTION IN ACERULOPLASMINEMIA BRAINS. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Blood Cells Mol Dis. (Nov-Dec 2002; 29(3)). Pp. 433-8. NEUROFERRITINOPATHY: A WINDOW ON THE ROLE OF IRON IN NEURODEGENERATION. Crompton DE, et.al. Blood Cells Mol Dis. (Nov-Dec . 2002; 29(3)). Pp. 522-31. MECHANISMS OF COPPER INCORPORATION INTO HUMAN CERULOPLASMIN. Hellman NE, et.al. J Biol Chem. (Nov 29, 2002; 277(48)). Pp. 46632-8. Epub (Sep 25, 2002). RADIOLOGIC FEATURES OF HALLERVORDEN SPATZ DISEASE. Asumal KB, Wasay M, Ali SN. J Pak Med Assoc. (Nov 2002; 52(11)). Pp. 528-30. HALLERVORDEN SPATZ SYNDROME (PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION) IN TWO SARDINIAN BROTHER WITH HOMOZYGOUS MUTATION IN PANK 2 GENE. Cossu G, et.al. J Neurol. (Nov 2002; 249(11)). Pp. 1599-600. RARE CAUSES OF HEREDITARY IRON OVERLOAD. Ponka, P. Semin Hematol (Oct 2002; 39(4)). Pp. 249-62. THE COPPER-IRON CONNECTION: HEREDITARY ACERULOPLASMINEMIA. Nittis T, Gitlin JD. Semin Hematol. (Oct 2002; 39(4)). Pp. 282-9. GENETIC DISORDERS AFFECTING PROTEINS OF IRON AND COPPER METABOLISM: CLINICAL IMPLICATIONS. Miyajima H. Intern Med. (Oct 2002; 41(10)). Pp. 762-9. NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, TYPE-I (NBIA-I) (FORMERLY HALLERVORDEN-SPATZ, DISEASE). PAR I: CLINICAL MANIFESTATION AND TREATMENT. Bertrand E. Neurol Neurochir of Poland. (Sep-Oct 2002; 36(5)) Pp. 947-58. Polish. ANEMIA AND IRON OVERLOAD DUE TO COMPOUND HETEROZYGOSITY FOR NOVEL CERULOPLASMIN MUTATIONS. Bosio S, et.al. Blood. (Sep 15, 2002; 100(6)). Pp. 2246-8. NOT ALL ABSENT SERUM CERULOPLASMIN IS WILSON DISEASE: A REVIEW OF ACERULOPLASMINEMIA. Harris ZL. J Investig Med. (Sep 2002; 50(5)). Pp. 236S-238S. GLUTATHIONE, IRON AND PARKINSON'S DISEASE. Bharath S, et.al. Biochemical Pharmacology. (Sep 2002; 64(5-6)). Pp. 1037-48. Review. INHERITED MOVEMENT DISORDERS. Sharma N; Standaert DG. Neurol Clin (Aug 2002; 20(3)). Pp. 759-78, vii. CLINICAL FEATURES AND MOLECULAR BASES OF NEUROACANTHOCYTOSIS. Rampoldi L; Danek A; Monaco AP. J Mol Med. (Aug 2002; 80(8)). Pp. 475-91. PALATAL TREMOR AND COGNITIVE DECLINE IN NEUROFERRITINOPATHY. Wills AJ, et.al. J Neurol Neurosurg Psychiatry. (July 2002; 73(1)). Pp. 91-2. AMINO ACID DETERMINANTS OF ALPHA-SYNUCLEIN AGGREGATION: PUTTING TOGETHER PIECES OF THE PUZZLE. Uversky VN; Fink AL. FEBS Lett. (July 2002; 522(1-3)). Pp. 9-13. HARP SYNDROME IS ALLELIC WITH PANTOTHENATE KINASE- ASSOCIATED NEURODEGENERATION. Ching KH, et al. Neurology (June 2002; 58(11)). Pp. 1673-4. ACERULOPLASMINEMIA - A GENETIC IRON STORAGE DISEASE]. Ocran KW, Schmidt HH. Z Gastroenterol. (Jun 2002; 40(6)). Pp. 479-81. ACERULOPLASMINEMIA: NEW CLINICAL, PATHOPHYSIOLOGICAL AND THERAPEUTIC INSIGHTS. Loréal O, et.al. J Hepatol. (Jun 2002; 36(6)). Pp. 851-6. HALLERVORDEN-SPATZ SYNDROME RESEMBLING A TYPICAL TOURETTE SYNDROME. Scarano V; Pellecchia MT; Filla A; Barone P. Mov Disord (May 2002; 17(3)). Pp. 618-20. THE GENETICS OF PRIMARY DYSTONIAS AND RELATED DISORDERS. Nemeth AH. Brain (April 2002; 125(Pt 4)). Pp. 695-721. ELECTROPHYSIOLOGICAL ASSESSMENT OF THE EFFECT OF INTRATHECAL BACLOFEN IN SPASTIC CHILDREN. Dachy, B & Dan, B. Clinical Neurophysiology. (Mar 2002; 113(3)). Pp. 336-40. GLUCOSE AND OXYGEN HYPOMETABOLISM IN ACERULOPLASMINEMIA BRAINS. Miyajima H, et.al. Internal Medicine. (Mar 2002; 41(3)). Pp. 186-90.b GLIAL FIBRILLARY ACIDIC PROTEIN IS GREATLY MODIFIED BY OXIDATIVE STRESS IN ACERULOPLASMINEMIA BRAIN. Kaneko K, et.al. Free Radic Res. (Mar 2002; 36(3)). Pp. 303-6. BIOCHEMICAL ANALYSIS OF A MISSENSE MUTATION IN ACERULOPLASMINEMIA. Hellman NE, Kono S, Miyajima H, Gitlin JD. J Biol Chem. (Jan 11, 2002; 277(2)). Pp.1375-80. Epub (Oct 31, 2001). DYSMORPHIC FACE IN TWO SIBLINGS WITH INFANTILE NEUROAXONAL DYSTROPHY. Seven M, et.al. Genetic Couns. (2002; 13(4)). Pp. 465-73. PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (HALLERVORDEN-SPATZ SYNDROME). Gordon N. European Journal of Paediatric Neurology. (2002; 6(5)). Pp. 243-7. RECENT DEVELOPMENTS IN THE PATHOLOGY OF PARKINSON'S DISEASE. Jellinger KA. Journal of Neural Transmission Suppl. (2002;(62)). Pp. 347-76. CERULOPLASMIN METABOLISM AND FUNCTION. Hellman NE, Gitlin JD. Annu Rev Nutr. (2002; 22). Pp. 439-58. Epub (Apr 4, 2002). |
|
SELECTIVE INSOLUBILITY OF ALPHA-SYNUCLEIN IN HUMAN LEWY
BODY DISEASES IS RECAPITULATED IN A TRANSGENIC MOUSE MODEL. Kahle PJ,
et al. Am J Pathol (Dec 2001; 159(6)). Pp. 2215-25.
MULTIPLE SYSTEM ATROPHY: CELLULAR AND MOLECULAR
PATHOLOGY. Burn DJ. Mol Pathol (Dec 2001; 54(6)). Pp. 419-26.
STABILIZATION OF PARTIALLY FOLDED CONFORMATION DURING
ALPHA-SYNUCLEIN OLIGOMERIZATION IN BOTH PURIFIED AND CYTOSOLIC
PREPARATIONS. Uversky VN; Lee HJ; Li J; Fink AL; Lee SJ. J Biol Chem
(Nov 2001; 276(47)). Pp. 43495-8.
LATE-ONSET NEURODEGENERATION WITH BRAIN IRON
ACCUMULATION TYPE 1: EXPANDING THE CLINICAL SPECTRUM. Racette BA;
Perry A; D'Avossa G; Perlmutter JS. Mov Disord (Nov 2001; 16(6)). Pp.
1148-52.
FIRST SCIENTIFIC WORKSHOP ON HALLERVORDEN-SPATZ
SYNDROME: EXECUTIVE SUMMARY. Hayflick, SJ. Pediatr Neurol (Aug 2001;
25(2)). Pp. 99-101.
STRIATAL AND PONTOCEREBELLAR HYPOPERFUSION IN
HALLERVORDEN-SPATZ SYNDROME. Castelnau P, et al. Pediatr Neurol (Aug
2001; 25(2)). Pp. 170-4.
CRANIAL MRI CHANGES MAY PRECEDE SYMPTOMS IN
HALLERVORDEN-SPATZZ SYNDROME. Hayflick SJ, et al. Pediatr Neurol (Aug
2001; 25(2)). Pp. 166-9.
JULIUS HALLERVORDEN'S WARTIME ACTIVITIES: IMPLICATIONS
FOR SCIENCE UNDER DICTATORSHIP. Shevell MI; Peiffer J. Pediatr Neurol
(Aug 2001; 25(2)). Pp. 162-5.
HGFRALPHA-4: A NEW MEMBER OF THE GDNF RECEPTOR FAMILY
AND A CANDIDATE FOR NBIA. Zhou B, et al. Pediatr Neurol (Aug 2001;
25(2)). Pp. 156-61.
IRON IN THE HALLERVORDEN-SPATZ SYNDROME. Koeppen AH;
Dickson AC. Pediatr Neurol (Aug 2001; 25(2)). Pp. 148-55.
IRON OVERLOAD, OXIDATIVE STRESS, AND AXONAL DYSTROPHY
IN BRAIN DISORDERS. Chiueh CC. Pediatr Neurol (Aug 2001; 25(2)).
Pp. 138-47.
SYSTEMIC IRON METABOLISM: A REVIEW AND IIMPLICATIONS
FOR BRAIN IRON METABOLISM. Rouault TA. Pediatr Neurol (Aug 2001;
25(2)). Pp. 130-7.
IRON AND IRON MANAGEMENT PROTEINS IN NEUROBIOLOGY.
Connor JR; Menzies SL; Burdo JR; Boyer PJ. Pediatr Neurol (Aug 2001;
25(2)). Pp. 118-29.
BASAL GANGLIA MOTOR FUNCTION IN RELATION TO
HALLERVORDEN-SPATZ SYNDROME. Mink JW. Pediatr Neurol (Aug 2001;
25(2)). Pp. 112-7.
HALLERVORDEN-SPATZ SYNDROME. Swaiman KF. Pediatr Neurol
(Aug 2001; 25(2)). Pp. 102-8.
A NOVEL PANTOTHENATE KINASE GENE (PANK2) IS
DEFECTIVE IN HALLERVORDEN-SPATZ SYNDROME. Zhou B, et al. Nat Genet
(Aug 2001; 28(4)). Pp. 345-9.
EXPRESSION OF STRESS PROTEINS ALPHA B-CRYSTALLIN,
UBIQUITIN, AND HSP27 IN PALLIDO-NIGRAL SPHEROIDS OF AGED RHESUS MONKEYS.
Schultz C, et al. Neurobiol Aging (Jul-Aug 2001; 22(4)). Pp. 677-82.
NEW GENES REVEAL MAJOR ROLE FOR IRON IN NEURODEGENERATION.
Senior K. Lancet (July 2001; 358(9278)). Pp. 302.
FOUR SIBLINGS WITH HALLERVORDEN-SPATZ DISEASE. Vaher U,
et al. Brain Dev (July 2001; 23(4)). Pp. 236-9.
HOW BROAD IS THE PHENOTYPE OF HALLERVORDEN-SPATZ DISEASE?
Hickman SJ, et al. Acta Neurol Scand. (Mar 2001; 103(3)). Pp. 201-3.
(HALLERVORDEN-SPATZ DISEASE). Kubota N; Jeshima A.
Ryoikibetsu Shokogun Shirizu (2001; 33)Pp. 791-2.
BOTULINUM TOXIN FOR TREATMENT OF JAW OPENING DYSTONIA IN
HALLERVORDEN-SPATZ SYNDROME. Dressler D; Wittstock M; Benecke R. Eur
Neurol (2001; 45(4)). Pp. 287-8.
HALLERVORDEN-SPATZ SYNDROME IN TWO SIBLINGS DIAGNOSED BY
CLINICAL FEATURES AND MAGNETIC RESONANCE IMAGING. Tiamkao S;
Nitinavakarn B; Jitpimolmard S. J Med Assoc. Thia (Dec 2000; 83(12)).
Pp. 1535-40.
THE EYE-OF-THE-TIGER SIGN. Guillerman RP. Radiology (Dec
2000; 217(3)). Pp. 895-6.
ALPHA-SYNUCLEIN ACCUMULATION IN A CASE OF
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION TYPE 1 (NBIA-1, FORMERLY
HALLERVORDEN-SPATZ SYNDROME) WITH WIDESPREAD CORTICAL AND BRAINSTEM-TYPE
LEWY BODIES. Neumann M, et al. Acta Neuropathol (Berl) (Nov 2000;
100(5)). Pp. 568-74.
LATE ADULT ONSET CHOREA WITH TYPICAL PATHOLOGY OF
HALLERVORDEN-SPATZ SYNDROME. Grimes DA; Lang AE; Bergeron C. J Neurol
Neurosurg Psychiatry. (Sept 2000; 69(3)). Pp. 392-5.
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, TYPE 1 IS
CHARACTERIZED BY ALPHA-BETA-AND GAMMA-SYNUCLEIN NEUROPATHOLGY. Galvin JE,
et al. Am J Pathol. (Aug 2000; 157(2)). Pp. 361-8.
(HALLERVORDEN-SPATZ DISEASE: FINDINGS IN THE
NIGROSTRIATAL SYSTEM). Hermann W, et al. Nervenarzt (Aug 2000; 71(8)).
Pp. 660-5. German
WIDESPREAD EXPRESSION OF ALPHA-SYNUCLEIN AND TAU
IMMUNOREACTIVITY IN HALLERVORDEN-SPATZ SYNDROME WITH PROTRACTED CLINICAL
COURSE. Saito Y, et al. J Neurol Sci (Aug 2000; 177(1)). Pp.
48-59.
INTRAFAMILIAL PHENOTYPIC VARIABILITY OF
HALLERVORDEN-SPATZ SYNDROME IN A TUNISIAN FAMILY. Gouider-Khouja N;
Miladi N; Belal S; Hentati F. Parkinsonism Relat Disord (July 2000;
6(3)). Pp. 175-179.
IRON INVOLVEMENT IN NEURAL DAMAGE AND MICROGLIOSIS IN
MODELS OF NEURODEGENERATIVE DISEASES. Shoham S; Youdim MB. Cell Mol Biol
(Noisy-le-grand). (June 2000; 46(4)). Pp. 743-60.
ADULT-ONSET HALLERVORDEN-SPATZ SYNDROME PRESENTING AS
CORTICAL DEMENTIA. Cooper GE; Rizzo M; Jones RD. Alzheimer Dis Assoc
Disord. (Apr-June 2000; 14(2)). Pp. 120-6.
ANESTHETIC MANAGEMENT FOR TWO-STAGE COMPUTER-ASSISTED,
STEREOTACTIC THALAMOTOMY IN A CHILD WITH HALLERVORDEN-SPATZ DISEASE.
Keegan MT, et al. J Neurosurg Anesthesiol (April 2000; 12(2)). Pp.
107-11.
SEPTEMBER 1999: 24 YEAR OLD FEMALE WITH PROGRESSIVE LOWER
EXTREMITY DYSTONIA, DYSARTHIA, DYSPHAGIA, AND MENTAL IMPAIRMENT.
Mourelatos Z; Golden JA. Brain Pathol. (Jan 2000; 10(1)). Pp. 171-2.
DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE USING MRI,
(123)I-BETA-CIT-SPEC AND (123)I-IBZM-SPECT. Hermann W., et al. Eur
Neurol (2000; 43(3)). Pp. 187-8.
(HALLERVORDEN-SPATZ DISEASE). Ohyagi Y; Kira J.
Ryoikibetsu Khokogun Shirizu. (2000; (30 pt 5)). Pp. 488-91.
SELF-INFLICTED INJURY IN A CASE OF HALLERVORDEN-SPATZ
DISEASE. Sheehy EC, et al. Int J Paediatr Dent (Dec 1999; 9 (4)). Pp.
299-302.
HALLERVORDEN-SPATZ DISEASE: MRI IMAGING. Shah J, et al. J
Postgrad Med (Oct-Dec 1999; 45(4)). Pp. 114-7.
HALLERVORDEN-SPATZ DISEASE IN AN ADULT PATIENT. Dymecki
J; Bertrand E; Tomankiewicz; Szuniewicz H. Folia Neuropathol (1999;
37(4)). Pp. 235-238.
|
|
HALLERVORDEN-SPATZ DISEASE: TWO NEW EARLY CHILDHOOD ONSET CASES. Pena JA, et al. J Child Neurol. (Jan 2000; 15(1)). Pp. 30-32. ALPHA-SYNUCLEIN IMMUNOREACTIVITY IS PRESENT IN AXONAL SWELLINGS IN NEUROAXONAL DYSTROPHY AND ACUTE TRAUMATIC BRAIN INJURY. Newell KL, et al. J Neuropathol Exp Neurol. (Dec 1999; 58(12)) Pp. 1263-1268. IRON DEPOSITS IN THE SUBTHALAMIC NUCLEI IN HALLERVORDEN-SPATZ DISEASE. Muller T, et al. Eur Neurol. (1999; 42(4)). Pp. 240-241.
INFANTILE NEUROAXONAL DYSTROPHY:
CLINICAL SPECTRUM AND DIAGNOSTIC CRITERIA, Nardocci N, et al. Neurology
(1999; 52) Pp. 1472-1478.
HALLERVORDEN-SPATZ DISEASE AND ACANTHOCYTES. Muthane UB, et al. Neurology (Nov 10,1999; 53(8)). Pp. 32A. WIDESPREAD OCCURRENCE OF ALPHA-SYNUCLEIN/NACP-IMMUNOREACTIVE NEURONAL INCLUSIONS IN JUVENILE AND ADULT-ONSET HALLERVORDEN-SPATZ DISEASE WITH LEWY BODIES. Wakabayashi K, et al. Neuropathol Appl Neurobiol. (Oct. 1999; 25(5)). Pp. 363-368. NEUROAXONAL DYSTROPHY WITH DYSTONIA AND PALLIDAL INVOLVEMENT. Simonati A, et al. Neuropediatrics (June 1999; 30(3)). Pp. 151-154. PROGRESSIVE PALLIDAL DEGENERATION. Hasegawa K. Ryoikibetsu Skokogun Shirizu(1999; 27 Pt.2) Pp. 74-77. Japanese GENERALIZED FREEZING IN HALLERVORDEN-SPATZ SYNDROME: CASE REPORT. Guimaraes J, et al. Eur J Neurol. (July 1999; 6(4)). Pp. 509-513. HALLERVORDEN-SPATZ SYNDROME. DIFFERENTIAL DIAGNOSIS OF EARLY ONSET DEMENTIA. Lechner C, et al. Nervenarzt (May, 1999; 70(5)). Pp. 471-475. INFANTILE NEUROAXONAL DYSTROPHY: NEURORADIOLOGICAL STUDIES IN 11 PATIENTS. Farina L, et al. Neuroradiology (May, 1999; 41(5)). Pp. 376-380. STEREOTACTIC PALLIDOTOMY IN A CHILD WITH HALLERVORDEN-SPATZ DISEASE. CASE REPORT. Justesen CR, et al. J Neurosurg (Mar 1999; 90(3)). Pp. 551-554. THE EYE OF THE TIGER SIGN IN CORTICAL-BASAL GANGLIONIC DEGENERATION. Molinuevo JL, et al. Mov Disord (Jan 1999; 14(1)). Pp. 169-171. THERAPEUTIC OBJECTIVES AND STRATEGIES IN NBIA 1 (HALLERVORDEN-SPATZ SYNDROME). Bruscoli F, et al. Minerva Anestesiol. (Nov 1998; 64(11)). Pp. 529-534. Italian LEWY BODY IN NEURODEGENERATION WITH BRAIN IRON ACCUMULATION TYPE 1 IS IMMUNOREACTIVE FOR ALPHA-SYNUCLEIN. Arawaka S, et al. Neurology (Sept 1998; 51(3)). Pp. 887-889. A CASE OF HALLEVORDEN-SPATZ DISEASE WITH MAGNETIC REASONING IMAGING DATA. Ruiz-Sandoval JL, et al. Rev Invest Clin (May-June 1998; 50(3)). Pp. 249-253. Spanish OPTIC ATROPHY AS THE FIRST SYMPTOM IN HALLERVORDEN-SPATZ SYNDROME. Battistella PA; Midena E; Suppiej A; Carollo C; Childs Nerv Syst (Mar 1998; 14(3)). Pp. 135-138. CEREBRAL HEMOSIDEROSIS RELATED TO HEREDITARY CERULOPLASMIN DEFICIENCY. CLINICAL FAMILIAL CASE STUDY. Servan J, et al. Rev Neurol(Paris) (Feb. 1998; 154(2)). Pp. 158-162. Review. French FAMILIAL MULTIPLE SYSTEM DEGENERATION ASSOCIATED WITH IRON DEPOSITION: DETERMINATION OF SUBCELLULAR LOCALIZATION OF ELEMENTARY IRON BY ENERGY-DISPERSIVE X-RAY ANALYSIS. Koga H; Kondo A; Kimura T; Takamatsu J; Clin Neuropathol (Jan-Feb 1998; 17(1)). Pp. 35-40. HALLERVORDEN-SPATZ DISEASE. Luengo A, et al. Rev Neurol (Dec 1997; 25(148)). Pp. 2052. Spanish PATHOLOGY OF THE CENTRAL NERVOUS SYSTEM IN CHESTER-ERDHEIM DISEASE: REPORT OF THREE CASES. Adle-Biassette H, et al. J Neuropathol Exp Neurol (Nov 1997; 56(11)). Pp. 1207-1216. HALLERVORDEN-SPATZ DISEASE. Hollody K, et al. Orv Hetil (Nov 1997; 138(48)). Pp. 3055-3057. Hungarian HALLERVORDEN-SPATZ DISEASE AND BOTULINUM TOXIN. Riol Diego M, et al. An Esp Pediatr(Oct 1997; 47(4)). Pp. 443-444. Spanish PROTON MAGNETIC RESONANCE SPECTROSCOPY IN STEELE-RICHARDSON-OLSZEWSKI SYNDROME. Davie CA, et al. Mov Disord. (Sept 1997; 12(5)). Pp. 767-771. BRAIN MAGNETIC RESONANCE IMAGING IN SUSPECTED EXTRAPYRAMIDAL CEREBRAL PALSY: OBSERVATIONS IN DISTINGUISHING GENETIC-METABOLIC FROM ACQUIRED CAUSES. Hoon AH Jr., et al. J Pediatr. (Aug 1997; 131(2)). Pp. 240-245. HALLERVORDEN-SPATZ DISEASE: LATE INFANTILE TYPE. Singhi PD; Mitra S; J Child Neurol (June 1997 12(4)). Pp. 281-282. USE OF DESFERRIOXAMINE IN THE TREATMENT OF ACERULOPLASMINEMIA. Miyajima H., Takahashi Y., Kamara T., Shimizu H., Sakai N., Gitlin, J. Annals of Neurology (Mar 1997; 41(3)). Pp. 404-407. SUPEROXIDE DISMUTASE-LIKE IMMUNOREACTIVITY IN SPHEROIDS IN HALLERVORDEN-SPATZ DISEASE. Nishiyama K; Murayama S; Nishimura Y; Asayama K; Kanazawa I; Acta Neuropathol (Berl) (Jan 1997; 93(1)). Pp. 19-23. HOMOZYGOSITY MAPPING OF HS SYNDROME TO CHROMOSOME 20p 12.3-p13. Taylor TD; Litt M; Kramer P; Pandolfo M; Angelini L; Nardocci N; Davis S; Pineda M; Hattori H; Flett PJ; Cilio MR; Bertini E; Hayflick SJ; Nat Genet (Dec 1996; 14 (4)). Pp. 479-481. NAMING OF SYNDROMES. Oppenheimer J R; Lancet (Dec 1996; 348(9042)). Pp. 1662. NAMING OF SYNDROMES. Shevell, M; Lancet (Dec 1996; 348(9042)). Pp. 1662 NAMING OF SYNDROMES. Morrison, P. Lancet (Dec 1996; 348(9042)). Pp. 1662 ATYPICAL DOPA RESPONSIVE PARKINSONISM IN A PATIENT WITH MEGALENCEPHlY, MIDBRAIN LEWY BODY DISEASE, AND SOME PATHOLOGICAL FEATURES OF HALLERVORDEN-SPATZ DISEASE. Tuite PJ; Provias JP; Lang AE; J Neurol Neurosurg Psychiatry; (Nov 1996; 61 (5)). Pp. 523- 527. NAMING OF SYNDROMES AND UNETHICAL ACTIVITIES: THE CASE OF HALLERVORDEN AND SPATZ. Harper PS; Lancet (Nov 1996; 348 (9036)). Pp. 1224-1225. CARE OF HALLERVORDEN-SPATZ DISEASE. Kong JC. Chung Hua Hu Li Tsa Chih (Sept 1996; 31(9)). Pp. 517-518. Chinese ACANTHOCYTOSIS, RETINITIS PIGMENTOSA, PALLIDAL DEGENERATION. REPORT OF TWO CASES WITHOUT SERUM LIPID ABNORMALITIES. Malandrini A; Cesaretti S; Mulinari M; Palmeri S; Fabrizi GM; Vilanova M; Parrotta E; Montagnani A; Montagnani M; Anichini M; Guazzi GC; J Neurol Sci (Sept 1996; 140 (1-2). Pp. 129-131. HALLERVORDEN-SPATZ DISEASE. Boyacigil S; Tokoglu F; Pasaoglu E; Ardic S; Comoglu S; Saka M; Ozturk S; Australas Radiol (Aug 1996; 40 (3)). Pp. 351-353. HALLERVORDEN-SPATZ SYNDROME: A CASE PRESENTATION. Ammann D, et al. Klin Monatsbl Augenheilkd (May 1996; 208(5)). Pp. 356-357. German CONTINUOUS INTRATHECAL BACLOFEN INFUSION FOR SYMPTOMATIC GENERALIZED DYSTONIA. Albright AL, et al. Neurosurgery (May 1996; 38(5)). Pp. 934-939. 'IN VIVO DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE'. Pena JA, et al. Dev Med Child Neurol (April 1996; 38(4)). Pp. 372-373. CLINICOPATHOLOGICAL STUDY OF FAMILIAL LATE INFANTILE HALLERVORDEN-SPATZ DISEASE: A PARTICULAR FORM OF NEUROACANTHOCYTOSIS. Malandrini A; Fabrizi GM; Bartalucci P; Salvadori C; Berti G; Sabo G; Guazzi GC; Childs Nerv Syst (Mar 1996; 12 (3)). Pp 155-160. HALLERVORDEN-SPATZ DISEASE (Letter; comment); Singhi PD; Indian Pediatr (Mar 1996; 33(3)). Pp. 252-253. A 75-YEAR-OLD MAN WITH PARKINSONISM AND SUDDEN DEATH. Nagaoka M, et al. No To Shinkei (Dec 1995; 47(12)). Pp. 1199-1208. THE NOSOLOGY OF HALLERVORDEN-SPATZ DISEASE. Halliday W; J Neurol Sci (Dec 1995; (134 Suppl)). Pp. 84-91. IS THERE A RATIONALE FOR IRON SUPPLEMENTATION IN THE TREATMENT OF AKATHISIA? A REVIEW OF THE EVIDENCE. Gold R, et al. J Clin Psychiatry (Oct 1995; 56(10)). Pp. 476-483. IN VIVO DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Ostergaard JR; Christensen T; Hansen KN; Dev Med Child Neurol (Sept 1995; 37 (9)). Pp. 827-833. TIME-DEPENDENT CHANGES IN IRON LEVELS AND ASSOCIATED NEURONAL LOSS WITHIN THE SUBSTANTIA NIGRA FOLLOWING LESIONS WITHIN THE NEOSTRIATUM/GLOBUS PALLIDUS COMPLEX. Sastry S, et al. Neuroscience (Aug 1995; 67(3)). Pp. 649-666. MYOPATHIC INVOLVEMENT IN TWO CASES OF HALLERVORDEN-SPATZ DISEASE. Malandrin A; Bonuccelli U; Parrotta E; Ceravolo R; Berti G; Guazzi GC; Brain Dev (July-Aug 1995; 17 (4)). Pp. 286-290. PRECOCIOUS PARKINSON’S DISEASE ASSOCIATED WITH “EYE-OF-THE-TIGER” TYPE PALLIDAL LESIONS. Barbosa ER, et al. Arq Neuropsiquiatr (June 1995; 53(2)). Pp. 294-297. Portugese HALLERVORDEN-SPATZ DISEASE. Kaushik A; Longia S; Jagadeesh R; Kishore V; Indian Pediatr (Apr 1995; 32(4)). Pp. 483-485. ACANTHOCYTOSIS, RETINITIS PIGMENTOSA, AND PALLIDAL DEGENERATION: A REPORT OF THREE PATIENTS, INCLUDING THE SECOND REPORTED CASE WITH HYPOPREBETALIPOPROTEINEMIA (HARP SYNDROME). Orrell RW, et al. Neurology (Mar 1995; 45(3 Pt 1)).Pp. 487-492. HALLERVORDEN-SPATZ DISEASE: PRESENTATION OF A NEW CASE. Pedrola D, et al. Rev Neurol (Jan-Feb 1995; 23(119)). Pp. 51-53. Spanish ULTRASTRUCTURE AND IMMUNOREACTIVITY OF DYSTROPHIC AXONS INDICATE A DIFFERENT PATHOGENESIS OF HALLERVORDEN-SPATZ DISEASE AND INFANTILE NEUROAXONAL DYSTROPHY. Malandrini A; Cavallaro T; Fabrizi GM; Berti G; Salvestroni R; Salvadori C; Guazzi GC; Virchows Arch (1995; 427 (4)). Pp. 415-421. MAGNETIC RESONANCE DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Bonetti M, et al. Radiol Med(Torino). (Dec 1994; 88(6)). Pp. 869-870. Italian. NON-ALZHEIMER NEUROFIBRILLARY TANGLES SHOW BETA-AMYLOID-LIKE IMMUNOREACTIVITY. Sherriff FE, et al. Neuroreport (Oct 1994; 5(15)). Pp. 1897-1900. OPTIC ATROPHY AS THE PRESENTING SIGN IN HALLERVORDEN-SPATZ SYNDROME. Casteels I, et al. Neuropediatrics (Oct 1994; 25(5)). Pp. 265-267. OCCIPITAL CONTRECOUP IN A CASE OF HALLERVORDEN-SPATZ DISEASE. Williams DJ, et al. Med Sci Law (Oct 1994; 34(4)). Pp. 353-356. HALLERVORDEN-SPATZ DISEASE: MR AND PATHOLOGIC FINDINGS. Savoiardo M; Halliday WC; Nardocci N; Strada L; D’Incerti L; Angelini L; Rumi V; Tesoro-Tess JD. Med Sci Law (Oct 1994; 34 (4). Pp. 353-356 & AMJ Neuroradiol (Jan-Feb 1993; 14 (1)). Pp. 155-162. CLINICAL AND MRI STUDY OF THE HALLERVORDEN-SPATZ SYNDROME: LONG-TERM FOLLOW-UP OF ONE CASE. Ou SF, et al. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih (Sept-Oct 1994; 35(5)). Pp. 439-443. Chinese HALLERVORDEN-SPATZ SYNDROME IN 2 VENEZUELAN PATIENTS. Pena JA, et al. Invest Clin (June 1994; 35(2)). Pp. 105-114. Spanish ANALYSIS OF GLIAL FIBRILLARY ACIDIC PROTEIN IN THE CEREBROSPINAL FLUID OF CHILDREN INVESTIGATED FOR ENCEPHALOPATHY. Ehlers S, et al. Neuropediatrics (June 1994; 25(3)). Pp. 129-133. COMPLEX TICS, STEREOTYPIES, AND COMPULSIVE BEHAVIOR AS CLINICAL PRESENTATION OF A JUVENILE PROGRESSIVE DYSTONIA SUGGESTIVE OF HALLERVORDEN-SPATZ DISEASE. Nardocci N, et al. Mov Disord (May 1994; 9(3)). Pp. 369-371. EARLY CLINICAL AND IMAGING (HIGH FIELD MRI) DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Feliciani M; Curatolo P; Neuroradiology (Apr 1994; 36 (3)). Pp. 247-24. PROGRESSIVE ATAXIA IN SWEDISH CHILDREN: A RE-EVALUATION STUDY. Ylitalo V, et al. Acta Neurol Scand. (Apr 1994; 89(4)). Pp. 299-302. HALLERVORDEN-SPATZ DISEASE WITH BILATERAL INVOLVEMENT OF GLOBUS PALLIDUS AND SUBSTANTIA NIGRA: MR DEMONSTRATION. Porter-Grenn L; Silbergleit R; Mehta BA; J Comput Assist Tomogr (Nov-Dec 1993; 17 (6)). Pp. 961-963. HALLERVORDEN-SPATZ DISEASE. Ohno M, et al. Nippon Rinsho(Nov 1993; 5(11)). Pp. 2957-2961. Japanese HALLERVORDEN-SPATZ SYNDROME IN TWO SIBLINGS DIAGNOSED BY THE CLINICAL FEATURES AND MAGNETIC RESONANCE IMAGING (MRI). Kim DW, et al. K Korean Med Sci(Oct 1993;8(5)). Pp. 329-333. MAGNETIC RESONANCE IN HALLERVORDEN-SPATZ DISEASE. Mauri Llerda JA, et al. Neurologia (Aug-Sept 1993; 8(7)). Pp. 235-238. Spanish CLINICAL FEATURES OF NEUROLEPTIC MAGLINANT SYNDROME IN BASAL GANGLIA DISEASE. SPONTANEOUS PRESENTATION ON A PATIENT WITH HALLERVORDEN-SPATZ DISEASE IN THE ABSENCE OF NEUROLEPTIC DRUGS. Hayashi K; Chihara E; Sawa T; Tanaka Y. Anaesthesia (Jun 1993; 48 (6)). Pp. 499-502. NEUROAXONAL DYSTROPHY COMBINED WITH DIFFUSE LEWY BODY DISEASE IN A YOUNG ADULT. Sugiyama H, et al. Clin Neuropathol(May-June 1993; 12(3)). Pp. 147-152. A CASE OF HALLERVORDEN-SPATZ SYNDROME WITH MARKED ATROPHY OF THE BRAINSTEM AND CEREBELLUM. Sodeyama N, et al. Rinsho Shinkeigaku (May 1993; 33(5)). Pp. 525-529. Japanese HALLERVORDEN-SPATZ SYNDROME: REPORT OF A CASE. Adamo Junior J. Arq Neuropsiquiatr (Mar 1993; 51(1)). Pp. 130-133. Portugese HALLERVORDEN-SPATZ SYNDROME AND MRI: THE “TIGER’S EYE”. ONE CASE. Trussart V; Leboucq N; Carlander B; Billiard M; Castan P; J Neuroradiol (Mar 1993; 20 (1)). Pp. 70-75. REHABILITATION OF PATIENTS WITH HALLERVORDEN-SPATZ SYNDROME. Seibel MO; Date ES; Zeiner H; Schwartz M; Arch Phys Med Rehabil (Mar 1993; (3)). Pp. 328-329. A CASE OF HALLERVORDEN-SPATZ SYNDROME DIAGNOSED ANTEMORTEMLY. Thajeb P. Chin Med J(Engl). (Feb 1993; 106(2)). Pp. 153-156. CONTRIBUTION OF NUCLEAR MAGNETIC IMAGING IN THE DIAGNOSIS OF HALLERVORDEN-SPATZ SYNDROME. Pedespan JM, et al. Arch Fr Pediatr (Jan 1993; 50(1)). Pp. 35-37. French PATHOLOGICAL ASSESSMENT OF MOVEMENT DISORDERS: REQUIREMENTS FOR DOCUMENTATION IN BRAIN BANKS. Jellinger KA, et al. J Neural Transm Suppl. (1993; 39). Pp. 173-184. Review IRON ACCUMULATION IN THE RAT BASAL GANGLIA AFTER EXCITATORY AMINO ACID INJECTIONS-DISSOCIATION FROM NEURONAL LOSS. Shoham S, et al. Exp Neurol (Nov 1992; 118(2)). Pp. 227-241. HALLERVORDEN-SPATZ DISEASE: CLINICAL AND MRI STUDY OF 11 CASES DIAGNOSED IN LIFE. Angelini L; Savoiardo M; J Neurol; (Oct 1992; 239 (8)). Pp. 417-425. A CASE OF HALLERVORDEN-SPATZ DISEASE: PROGRESSIVE AND INTRACTABLE DYSTONIA CONTROLLED BY BILATERAL THALAMOTOMY. Tsukamoto H; Inui K; Taniike M; Nishimoto J; Midorikawa T; Okada S; Brain Dev (July 1992; 14(4)). Pp. 269-272. AN AUTOPSIED CASE OF JUVENILE PARKINSONISM AND DEMENTIA, WITH A WIDESPREAD OCCURRENCE OF LEWY BODIES AND SPHEROIDS. Odawara T, et al. Clin Neuropathol (May-June 1992: 11(3)). Pp. 131-134. CONTINUOUS, GENERALIZED, HIGH-VOLTAGE FAST ACTIVITY AND FIRDA IN TWO CHILDREN. Mutoh K, et al. Clin Electroencephalogr. (Apr 1992; 23(2)). Pp. 68-71. HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA, AND PALLIDAL DEGENERATION (HARP SYNDROME). Higgins JJ, et al. Neurology (Jan 1992; 42(1)). Pp. 194-198. GLOBUS PALLIDUS CALCIFICATION IN DOWN SYNDROME WITH PROGRESSIVE NEUROLOGIC DEFICITS. Okano S, et al. Pediatr Neurol. (Jan-Feb 1992; 8(1)). Pp. 72-74. NUCLEAR MAGNETIC RESONANCE TOMOGRAPHY AND DIFFERENTIAL DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Schneider S, et al. Nervenarzt (Feb 1992; 63(2)). Pp. 105-107. German LATE ONSET FAMILIAL HALLERVORDEN-SPATZ DISEASE: MR FINDINGS IN TWO SISTERS. Ambrosetto P; Nonni R; Bacci A; Gobbi G; AJNR Am J Neuroradiol (Jan-Feb 1992; 13 (1)). Pp. 394-396. CLINICOPATHOLOGIC CORRELATION AND PATHOGENESIS OF OCULAR AND CENTRAL NERVOUS SYSTEM MANIFESTATIONS IN HALLERVORDEN-SPATZ SYNDROME. Tripathi RC, et al. Acta Neuropathol (Berl) (1992; 83(2)). Pp. 113-119. FOLLOW-UP MAGNETIC RESONANCE IMAGING IN HALLERVORDEN-SPATZ DISEASE. Brouwer OF; Laboyrie PM; Peters AC; Vielvoye GJ; Clin Neurol Neurosurg; (1992; (94)). Suppl: Pp. 557- 560. HALLERVORDEN-SPATZ SYNDROME AND BRAIN IRON METABOLISM. Swaiman K; Arch Neurol (Dec 1991; 48(12)). Pp. 1285-1293. A CASE OF HALLERVORDEN-SPATZ SYNDROME--CLINICAL COURSE AND SUCCESSIVE FINDINGS OF BRAIN CT. Yamada T. No To Hattatsu (Nov 1991; 23(6)). Pp. 628-630. Japanese HALLERVORDEN-SPATZ SYNDROME. INDICATIVE FINDINGS IN CRANIAL COMPUTERIZED AND MAGNETIC RESONANCE TOMOGRAPHYJ FOR INTRA VITAM DIAGNOSIS. Kurlemann G, et al. Monatsschr Kinderheilkd (Sept 1991; 129(9)). Pp. 626-628. German HALLERVORDEN-SPATZ DISEASE? Raine CS Brain Pathol. (Jul 1991; 1(4)). Pp. 328. NEW X-LINKED MENTAL RETARDATION DISORDER WITH DANDY-WALKER MALFORMATION, BASAL GANGLIA DISEASE, AND SEIZURES. Pettigrew AL, et al. Am J Med Genet. (Feb-Mar 1991; 38(2-3)). Pp. 200-207. PALLIDO-NIGRO-LUYSIAN ATROPHY, PROGRESSIVE SUPRANUCLEAR PALSY AND ADULT ONSET HALLERVORDEN-SPATZ DISEASE: A CASE OF AKINESIA AS A PREDOMINANT FEATURE OF PARKINSONISM. Yamamoto T, et al. J Neurol Sci. (Jan 1991; 101(1)). Pp. 98-106. A FAMILIAL SYNDROME OF DYSTONIA, BLEPHASOSPASM, AND PIGMENTARY RETINOPATHY. Coppeto JR, et al. Neurology (Sept 1990; 40(9)). Pp. 1359-1363. THE ROLE OF MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Tabuchi M, et al. Rinsho Shinkeigaku (Sept 1990; 30(9)). Pp. 972-977. Japanese OSMIOPHILIC DEPOSITS IN CYTOSOMES IN HALLERVORDEN-SPATZ SYNDROME. Zupanc ML, et al. Pediatr Neurol (Sept-Oct 1990; 6(5)). Pp. 349-352. IMPORTANTANCE OF MAGNETIC RESONANCE IN THE DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE: PRESENTATION OF A CASE WITH FAMILIAL HISTORY. Perez Sempere A, et al. Neurologia (Aug-Sept 1990; 5(7)). Pp. 252-253. Spanish SPORADIC LATE-ONSET HALLERVORDEN-SPATZ DISEASE PRESENTING AS PARKINSONISM IN A CHINESE PATIENT. Wang LN, et al. Chin Med J (Engl) (Aug 1990; 103(8)). Pp. 686-688. ADULT ONSET HALLERVORDEN-SPATZ SYNDROME OR SEITELBERGER’S DISEASE WITH LATE ONSET: VARIANTS OF THE SAME ENTITY? A CLINICO-PATHOLOGICAL STUDY. S. Gaytan-Garcia et al.; Clin Neuropathol (May-June 1990; 9 (3)). Pp. 136-142. SOMATOSENSORY EVOKED POTENTIALS IN HALLERVORDEN-SPATZ-NEUROAXONOL-DYSTROPHY COMPLEX WITH DORSAL COLUMN INVOLVEMENT. Mutoh K; Okuno T; Ito M; Mikawa H; Clin Electroencephalogr; (April 1990; 21 (2)). Pp. 58-66. FOLLOW-UP MR STUDIES IN HALLERVORDEN-SPATZ DISEASE. Gallucci M; Cardona F; Arachi M; Splendiani A; Bozzao A; Passariello, R. J Comput Assist Tomogr (Jan-Feb 1990; 14 (1)). Pp. 329-333. LIVER AND PITUITARY ABNORMALITIES IN HALLERVORDEN-SPATZ DISEASE. Williams DJ; Ironside JW; J of Neurol, Neurosurgery and Psychiatry; ( Dec 1989 (52)). Pp. 1410-1414. THE SUPERIOR MESENTERIC ARTERY SYNDROME: AN UNUSUAL COMPLICATION IN A PATIENT WITH THE HALLERVORDEN-SPATZ SYNDROME. Massa G, et al. Acta Gastroenterol Belg. (Sept-Dec 1989; 52(5-6)). Pp. 436-440. HALLERVORDEN-SPATZ SYNDROME WITH ACANTHOCYTOSIS. Kohler B. Monatsschr Kinderheilkd (Sept 1989; 137(9)). Pp. 616-619. German HALLERVORDEN-SPATZ DISEASE. Miller MB. J Clin Psychiatry (Aug 1989; 50(8)). Pp. 309. MRI IN INFANTILE NUEROAXONAL DYSTROPHY. Ito M, et al. Pediatr Neurol. (Jul-Aug 1989; 5(4)). Pp. 245-248. MAGNETIC RESONANCE IMAGING IN PATHOLOGICALLY PROVEN HALLERVORDEN-SPATZ DISEASE. Schaffert D; Johnsen S; Johnson P; Drayer B; Neurology (Mar 1989 (39)). Pp. 440-442. HALLERVORDEN-SPATZ DISEASE IN A PSYCHIATRIC SETTING. Morphy MA; Feldman J; Kilburn G; J Clin Psychiatry; (Feb 1989; 50(2)). Pp. 66-68. MAGNETIC RESONANCE IMAGING AND EXTRAPYRAMIDAL MOVEMENT DISORDERS. Drayer BP. Eur Neurol. (1989: 29 Suppl 1) Pp. 9-12. CASE 1, 1989: JUVENILE-ONSET PARKINSONISM, DYSTONIA, AND PYRAMIDAL TRACT SIGNS. Kang UJ, et al. Mov Disord. (1989; 4(4)). Pp. 363-370. HALLERVORDEN-SPATZ DISEASE: CLINICAL AND MAGNETIC RESONANCE IMAGING CORRELATIONS. Sethi KD; Adams RJ; Loring DW; El Gammal T; Ann Neurol (Nov 1988; 24 (5)). Pp. 692-694. MR IMAGING OF A GROUP I CASE OF HALLERVORDEN-SPATZ DISEASE. Mutoh K, et al. J Comput Assist Tomogr (Sept-Oct 1988; 12(5)). Pp. 851-853. HALLERVORDEN-SPATZ DISEASE IN TWIN PATIENTS. Makevic M, et al. Vojnosanit Pregl. (July-Aug 1988; 45(4)). Pp. 305-307 Serbo-Croatian (Roman) “HALLERVORDEN-SPATZ SYNDROME--INFANTILE NEUROAXONAL DYSTROPHY” COMPLEX. CASE REPORT. Bresolin AU, et al. Arq Neuropsiquiatr. (Mar 1988; 46(1)). Pp. 69-72. MINERALIZATION OF THE BASAL GANGLIA DETECTED BY CT IN HALLERVORDEN-SPATZ SYNDROME. Tennison MB, et al. Neurology (Jan 1988; 38(1)). Pp. 154-155. ADVANCES IN THE STUDIES OF THE PATHOGENESIS, TREATMENT AND PREVENTION OF GENETICALLY DETERMINED DISEASES OF THE EXTRAPYRAMIDAL TRACTS. Wald I, et al. Neurol Neurochir Pol. (Jan-Feb 1988; 22(1)). Pp. 1-4. Polish MAGNETIC RESONANCE IMAGING OF DYSTONIC STATES. Rutledge JN, et al. Adv Neurol (1988; 50). Pp. 265-275. MAGNETIC RESONANCE TOMOGRAPHY CONFIRMS THE DIAGNOSIS OF HALLERVORDEN-SPATZ DISEASE. Scheer PJ, et al. Padiatr Padol. (1988; 23(3)). Pp. 245-252. THE NEUROPATHOLOGY OF PARKINSON SYNDROME. Gray F. Rev Neurol (Paris) (1988; 144(4)). Pp. 229-248. LATE ONSET PARKINSONIAN SYNDROME IN HALLERVORDEN-SPATZ DISEASE. Alberca R; Rafel E; Chinchon I; Vadillo J; Navarro A; J of Neurol, Neurosurgery, and Psychiatry; (Dec 1987 50(12)). Pp. 1665-1668. MR IMAGING IN A CASE OF HALLERVORDEN-SPATZ DISEASE. Tanfani G; Mascalchi M; Dal Pozzo GC; Taverni N; Saia A; Trevisan C; J Comput Assist Tomogr (Nov-Dec1987; 11(6)). Pp. 1057-1058. ADULT ONSET HALLERVORDEN-SPATZ DISEASE WITH NEUROFIBRILLARY PATHOLOGY. A DISCRETE CLINICOPATHOLOGICAL ENTITY. Eidelberg D, et al. Brain (Aug 1987; 110(Pt 4)). Pp. 993-1013. COMPUTED TOMOGRAPHY IN HALLERVORDEN-SPATZ DISEASE. Boltshauser E, et al. Neuropediatrics (May 1987; 18(2)). Pp. 81-83. ULTRASTRUCTURAL STUDY OF CONJUNCTIVE BIOPSIES IN METABOLIC DISEASES OF THE NERVOUS SYSTEM. Rosemberg S, et al. Arq Neuropsiquiatr (Mar 1987; 45(1)). Pp. 7-15. Portugese NEW COMPUTED TOMOGRAPHY SCAN FINDING IN HALLERVORDEN-SPATZ SYNDROME. Vankirk M; Larsen P; O’Connor P; J of Clin Neuro-ophthalmology; (June1986; 6 (2)). Pp. 86-90. IDIOPATHIC PARKINSON’S DISEASE AND THE LEWY BODY DISORDERS. Gibb WR. Neuropathol Appl Neurobiol. (May-June 1986; 12(3)).Pp. 223-234. LYMPHOCYTE AUTOFLUORESCENCE: A SCREENING PROCEDURE FOR NEURODEGENERATIVE DISEASES. Hawkins EP, et al. Pediatr Neurol (May-June 1986; 2(3)). Pp. 160-166. COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING IN CHILDREN WITH RARE MOVEMENT DISORDERS. Sartor K, et al. Acta Radiol Suppl. (1986; 369) Pp. 658-663. HALLERVORDEN-SPATZ DISEASE: CYSTEINE ACCUMULATION AND CYSTEINE DIOXYGENASE DEFICIENCY IN THE GLOBUS PALLIDUS. Perry TL; Norman MG; Yong VW; Whiting S; Crichton JU; Hansen S; Kish SJ; Ann Neurol (Oct 1985; 18). Pp. 482-489. MR IMAGING OF HALLERVORDEN-SPATZ DISEASE. Littrup PJ, et al. J Comput Assist Tomogr (May-June 1985; 9(3)). Pp. 491-493. LATE-ONSET HALLERVORDEN-SPATZ DISEASE PRESENTING AS FAMILIAL PARKINSONISM. Jankovic J, et al. Neurology (Feb 1985; 35(2)). Pp. 227-234. HALLERVORDEN-SPATZ
DISEASE WITH LEWY BODIES. Antoine JC, et al. Rev Neurol (Paris) (1985;
141(12)). Pp. 806-809. |